Medical Devices


This report details the complete range of products and technologies in spine surgery, including the surgical management of spine disorders, diseases and trauma, with treatments including use of grafts, demineralized bone, fusion, stabilization, disc replacement, nucleus replacement, vertebroplasty, kyphoplasty, imaging, minimally invasive surgical technologies, energy-based therapies and biologics. The report details current clinical and technology developments in the huge and rapidly growing spine surgery technologies worldwide market, with data on products in development and on the market; market size and forecast; competitor market shares; competitor profiles; and market opportunity.

This report is a detailed market and technology assessment and forecast of the products and technologies in the management of diseases and disorders of the spine. The report describes diseases and disorders of the spine, encompassing congenital disorders, inflammatory and infectious diseases; degenerative diseases; herniations, stenoses, myelopathies and other “mechanical” disorders of the spine; spinal trauma; tumors of the spine; and others. The report characterizes the patient populations, their current clinical management, and trends in clinical management as new techniques and technologies are expected to be developed and emerge. The report details the currently available products and technologies, and manufacturer offerings. The report details products and technologies under development and markets for each in spine surgery. The report provides a current and forecast assessment of the worldwide markets for these technologies, with geographic segmentation by U.S. & Canada, European Union (detailing France, United Kingdom, Germany, Italy and Spain), Japan and Rest of World. The report provides emphasis on the market impact of new technologies through the coming decade, profiling nearly 100 active companies in this industry, with comprehensive detail on key companies, providing data on their current products, current market position and products under development.

Table of Contents:

Executive Summary
Non-fusion products
Disc arthroplasty (total disc replacement)
Nuclear arthroplasty
European Union
Asia-Pacific
Rest of World
Selected company-related events
Medtronic
LDR Spine
Synthes Spine
Disc Motion Technologies
Spine Structure
Products and technologies
CMS, carriers reverse decision on artificial discs
Cost effectiveness

Section 1:          The Spine: Structure, Disorders, Treatment
1.1         Overview: Spine Structure
1.2         Diseases and disorders of the spine
1.2.1             Congenital Disorders
1.2.2             Inflammatory and Infectious Diseases of the Spine
1.2.3             Degenerative Diseases of the Spine
1.2.4             Mechanical Disorders of the Spine
1.2.5             Spinal Trauma
1.2.6             Tumors of the Spine
1.3         Spine management
1.3.1             Clinical: the SPORT Study
1.3.2             Diagnostic studies
1.3.3             Surgical procedures of the spine
1.3.4             Minimally Invasive Procedures
1.3.5             Minimally Invasive Bone Grafting Procedures
1.3.6             Acupuncture for treatment of chronic low back pain

Section 2:          Products and Technologies
2.1         Bone grafts and bone graft substitutes
2.2         Demineralized bone matrix (DBM)
2.2.1             Particle based DBM
2.2.2             Biomimetic matrix bone substitute
2.2.3             Bone morphogenic proteins (BMPs)
2.3         Spinal fusion and fixation products and technologies
2.3.1             Spine surgery instrumentation
2.3.2             Cervical fusion devices
2.3.3             Interbody fusion devices
2.3.4             Posterior dynamic stabilization systems
2.4         Non-fusion products and technologies
2.4.1             Disc arthroplasty
2.4.2             Nuclear arthroplasty and nuclear disc prostheses
2.4.3             Facet repair and replacement
2.5         Vertebroplasty and kyphoplasty
2.5.1             Vertebral compression fracture treatment technologies
2.6         Advances in spinal image-guided surgery
2.6.1             Medtronic’s StealthStation
2.6.2             GE Healthcare’s Fluoro-Spine
2.6.3             Elekta’s Axesse system
2.6.4             Zimmer’s ORTHOsoft Navitrack® FluoroSpine® System
2.7         Products and technologies for minimally invasive spinal surgery
2.7.1             ArthroCare’s spineWand
2.7.2             Medtronic’s MAST™ portfolio
2.7.3             NuVasive’s Maximum Access Surgery (MAS)
2.7.4             Abbott Spine’s Harmony Retractor
2.7.5             Globus transforaminal TDR device
2.8         Energy-based therapies
2.8.1             Bone growth stimulators
2.8.2             Intradiscal Electrothermal Therapy (IDET)
2.9         Biologics

Section 3:          Market Size, Forecast and Competitor Shares
3.1         Global market size, forecast and competitor shares
3.2         USA & Canada
3.2.1             Bone grafts and bone graft substitutes
3.2.2             Spinal fusion and fixation products
3.2.3             Non-fusion products
3.2.4             Vertebroplasty and Kyphoplasty
3.2.5             Interspinous process spacers (ISP)
3.2.6             Computer assisted image guided surgery products
3.3         European Union
3.3.1             United Kingdom
3.3.2             France
3.3.3             Germany
3.3.4             Italy
3.3.5             Spinal fusion and fixation products
3.3.6             Non-fusion products
3.3.7             Total disc replacement
3.3.8             Nucleus replacement
3.3.9             Interspinous process spacers (ISPs)
3.3.10           Kyphoplasty
3.3.11           Image Guided Surgery Products Market
3.4         Asia-Pacific
3.4.1             Spinal fusion and fixation products
3.4.2             Non-fusion products
3.4.3             Image guided surgery products
3.5         Rest of World

Section 4:          Regulatory, Cost and Reimbursement Issues
4.1         Regulatory Issues Associated with Spine Treatments, Materials and Methods
4.1.1             Regulatory issues regarding off-label usage
4.1.2             Changes to European Device Safety Regulations
4.1.3             NICE and dynamic stabilization procedures
4.2         Reimbursement Developments
4.2.1             CMS, carriers reverse decision on artificial discs
4.2.2             CMS reverses stand on two spinal fusion procedures
4.2.3             ArthroCare and DiscoCare
4.2.4             Bone growth factor reimbursement issues
4.2.5             CMS investigates Thermal Intradiscal Therapy
4.2.6             CMS announces new ICD-9-CM spinal procedure codes
4.2.7             Wellmark and energy-based treatments
4.3         Cost effectiveness

Section 5:          Company Profiles
5.1         Abbott Spine
5.2         AlloSource
5.3         Alphatec Holdings, Inc.
5.4         Altiva Corporation
5.5         Anulex Technologies, Inc.
5.6         ApaTech
5.7         Applied Spine Technologies
5.8         ArthroCare Corporation
5.9         A-Spine Holding Group Corporation
5.10       Axial Biotech
5.11       AxioMed Spine Corporation
5.12       B. Braun/Aesculap, Inc.
5.13       BioAssets Development Corporation
5.14       Biomet
5.15       Biorthex, Inc.
5.16       Blackstone Medical, Inc
5.17       BrainLAB
5.18       Cardinal Health
5.19       Cervitech
5.20       Changzhou Kanghui
5.21       Co.Don AG
5.22       CoLigne AG
5.23       Cook Group
5.24       CoreSpine Technologies LLC
5.25       Corin Group
5.26       Cortek, Inc
5.27       Cryolife, Inc.
5.28       Cyberkinetics Neurotechnology Systems
5.29       Cytori Therapeutics
5.30       DePuy Spine/J&J
5.31       Disc Dynamics
5.32       Disc Motion Technologies
5.33       Encore Medical Corporation / DJO Surgical (ReAble Therapeutics)
5.34       Facet Solutions
5.35       Fixano (Small Bone Innovations)
5.36       GE Healthcare
5.37       Gentis, Inc
5.38       Globus Medical
5.39       GMReis
5.40       HydroCision
5.41       [Innovative Spinal Technologies — ceased operations January 2009]
5.42       Integra LifeSciences
5.43       Integra Radionics
5.44       Interpore Cross
5.45       Interventional Spine
5.46       Invibio
5.47       LDR Holding Corporation
5.48       LifeNet Health, Inc.
5.49       Mazor Surgical Technologies Ltd
5.50       Medtronic, Inc
5.51       Medtronic Sofamor Danek
5.52       Medtronic Surgical Navigation
5.53       Mekanika, Inc.
5.54       Merck & Co., Inc.
5.55       MiMedx
5.56       Misonix
5.57       MTF (Musculoskeletal Transplant Foundation)
5.58       NPS Pharmaceuticals
5.59       N Spine, Inc. (Synthes)
5.60       NuVasive, Inc.
5.61       Ortho Development Corporation
5.62       Orthofix International, N.V.
5.63       OrthoVita
5.64       Osiris Therapeutics
5.65       Osteotech, Inc.
5.66       Ortosintese
5.67       Paradigm Spine, LLC
5.68       Pitkar
5.69       Praxim
5.70       Ranier Technology Limited
5.71       Raymedica, Inc.
5.72       Regeneration Technologies, Inc
5.73       Scient’X
5.74       SeaSpine, Inc.
5.75       Sharma Surgical
5.76       Small Bone Innovations, LLC
5.77       Smart Disc
5.78       Smith & Nephew
5.79       SpinalMotion
5.80       SpineMedica Corporation
5.81       Spineology
5.82       SpineOvations
5.83       SpineVision Inc
5.84       Spine Wave, Inc.
5.85       Stryker Corporation
5.86       Stryker Instruments
5.87       Stryker Spine
5.88       Synthes Spine Solutions
5.89       Theken Spine
5.90       TranS1, Inc.
5.91       Trimedyne, Inc.
5.92       Ulrich Medical GmbH
5.93       Valleylab
5.94       Vertebron Inc.
5.95       Waston Medical
5.96       Wright Medical Technology
5.97       X-spine Systems, Inc.
5.98       Zimmer Spine
Appendix:  Company Directory

List of Exhibits

Exhibit ES-1: Total Global Spine Surgery Market, 2008-2017
Exhibit ES-2: Total Global Spine Surgery Market, 2008-2017
Exhibit ES-3: Global Spine Surgery Market by Segment, in USD Terms
Exhibit ES-4: Global Spine Surgery Market by Percentage and Segments, 2008
Exhibit ES-5: Major Spine Market Segments, 2008-2017
Exhibit ES-6: Key Factors Driving Growth in the Global Spine Surgery Market
Exhibit ES-7: Global Spine Surgery Market Shares, 2008
Exhibit ES-8: US & Canadian Market for Spine Surgery Devices
Exhibit ES-9: US Company Market Shares for Spine Surgery Devices, 2008
Exhibit ES-10: Total Global Spine Surgery Market, by Region, 2008
Exhibit ES-11: Total EU Spine Surgery Market, 2008-2017
Exhibit ES-12: Total EU Spine Surgery Market, 2008-2017
Exhibit ES-13: EU Spine Surgery Market Shares, 2008
Exhibit ES-14: Asia-Pacific: Total Spine Surgery Market, 2008-2017
Exhibit ES-15: Asia-Pacific: Total Spine Surgery Market, 2008-2017
Exhibit ES-16: Asia-Pacific: Spine Surgery Market Shares, 2008
Exhibit ES-17: Rest of World Spine Surgery Market Shares, 2008
Exhibit ES-18: ROW, Spine Surgery Markets, 2008-2017
Exhibit ES-19: Lateral and Posterior Views of the Spine
Exhibit ES-20: Human Spine Structure Showing Vertebrae, Intervertebral Discs, and Spinal Cord
Exhibit ES-21: US Census figures and projections, ages 65 and up, 1900-2050.
Exhibit ES-22: Number & Percentage of U.S. Population over Age 65, 1910–2050
Exhibit ES-23: Mechanical Disorders of the Spine
Exhibit ES-24: Start-up companies and areas of interest
Exhibit ES-25: CPT spinal fusion codes now allowed by CMS
Exhibit ES-26: Summary of CMS Medicare cost data

Exhibit 1-1: Lateral and Posterior Views of the Spine
Exhibit 1-2: Human Spine Structure Showing Vertebrae, Intervertebral Discs, and Spinal Cord
Exhibit 1-3: Components of the Human Spine
Exhibit 1-4: US Census figures and projections, ages 65 and up, 1900-2050.
Exhibit 1-5: Number & Percentage of U.S. Population over Age 65, 1910–2050
Exhibit 1-6: Congenital Disorders of the Spine
Exhibit 1-7: Inflammatory and Infectious Diseases of the Spine
Exhibit 1-8: Degenerative Diseases of the Spine
Exhibit 1-9: Estimated Annual Number of Fractures Due to Osteoporosis in the U.S. (Total: Over 1.5 Million)
Exhibit 1-10: Mechanical Disorders of the Spine
Exhibit 1-11: Location, Effects, and Incidence of Major Lumbar Disc Herniations
Exhibit 1-12: Clinical Features—Radiculopathy by Spinal Level
Exhibit 1-13: Causes of Trauma to Spinal Regions
Exhibit 1-14: Tumors of the Spine
Exhibit 1-15: Traditional (“Open”) Spinal Procedures
Exhibit 1-16: Estimated Number of Spinal Fusion Procedures Performed in the U.S., 2005–2015
Exhibit 1-17: Minimally Invasive Spinal Procedures

Exhibit 2-1: Spinal Allografts: Vendors and Products
Exhibit 2-2: Hydroxyapatite Bone Substitutes: Vendors, Products
Exhibit 2-3: Bone growth stimulatory proteins, peptides and devices
Exhibit 2-4: Fusion instrumentation companies
Exhibit 2-5: Developers of Interspinous Process Spacers
Exhibit 2-6: Developers of Total Disc Replacements
Exhibit 2-7: Artificial Cervical Discs Currently in US Clinical Trials
Exhibit 2-8: Artificial Cervical Discs Currently Available in the EU
Exhibit 2-9: Total disc replacement devices
Exhibit 2-10: Developers of Prosthetic Disc Nuclei
Exhibit 2-11: Nucleus replacement implants
Exhibit 2-12: Current nucleus arthroplasty motion preservation IDE pilot studies
Exhibit 2-13: Bone growth stimulatory proteins, peptides and devices
Exhibit 2-14: Cellular therapies: manufacturers and product
Exhibit 2-15: Other start-up companies and areas of interest

Exhibit 3-1: Total Global Spine Surgery Market, 2008-2017
Exhibit 3-2: Total Global Spine Surgery Market, 2008-2017
Exhibit 3-3: Global Spine Surgery Market by Segment, in USD Terms
Exhibit 3-4: Global Spine Surgery Market by Percentage and Segments, 2008
Exhibit 3-5: Key Factors Driving Growth in the Global Spine Surgery Market
Exhibit 3-6: Major Spine Market Segments, 2008-2017
Exhibit 3-7: Global Spine Surgery Market Shares, 2008
Exhibit 3-8: US & Canadian Market for Spine Surgery Devices
Exhibit 3-9: US & Canadian Market for Spine Surgery Devices
Exhibit 3-10: US Company Market Shares for Spine Surgery Devices, 2008
Exhibit 3-11: Usage of Bone Grafts and Bone Graft Substitutes in Spinal Fusion Procedures (excluding BMPs)
Exhibit 3-12: US Market for Bone Graft Substitutes
Exhibit 3-13: US Market for Spine-Related Orthobiologics, 2008-2017
Exhibit 3-14: US & Canadian Market for Spinal Fusion and Fixation Devices
Exhibit 3-14B:  US & Canadian Spinal Fusion Procedures by Segment (Cervical, Lumbar, Thoracic), 2008-2017
Exhibit 3-15: Number of Spinal Fusions
Exhibit 3-16: US & Canadian Market for Spinal Fusion and Fixation Devices
Exhibit 3-17: US Market Shares, Spinal Fusion and Fixation Devices, 2008
Exhibit 3-18: US Market Shares, Spinal Fusion and Fixation Devices, 2008
Exhibit 3-19 Total US Non-Fusion Device Market
Exhibit 3-20: Total US Non-Fusion Device Market
Exhibit 3-21: US Annulus Repair Market, 2009-2015
Exhibit 3-22: US Annulus Repair Market, 2009-2015
Exhibit 3-23: Total Market for Disc Arthroplasty (Cervical Plus Thoracolumbar)
Exhibit 3-24: US Market for Cervical Disc Replacement
Exhibit 3-25: US Market for Cervical Disc Replacement
Exhibit 3-26: US Market for Thoracolumbar Disc Replacement
Exhibit 3-27: US Market for Thoracolumbar Disc Replacement
Exhibit 3-28: US & Canadian Markets for Nuclear Arthroplasty
Exhibit 3-29: US Market for Nucleus Replacement
Exhibit 3-30: Total US Market for Vertebroplasty and Kyphoplasty
Exhibit 3-31: US Market for Vertebroplasty
Exhibit 3-32: US Market for Vertebroplasty
Exhibit 3-33: US Market for Kyphoplasty
Exhibit 3-34: US Market for Kyphoplasty
Exhibit 3-35: 2008 US Market Shares, Combined Vertebroplasty/Kyphoplasty
Exhibit 3-36: US Interspinous Process Spacers Market, 2008-2017
Exhibit 3-37: US Interspinous Process Spacers Market, 2008-2017
Exhibit 3-38: US Market for Image Guided Surgery Devices
Exhibit 3-39: US Market for Image Guided Surgery Devices
Exhibit 3-40: US Competitor Shares, Image Guided Surgery Devices, 2008
Exhibit 3-41: Total Global Spine Surgery Market, by Region, 2008
Exhibit 3-42: Total EU Spine Surgery Market, 2008-2017
Exhibit 3-43: Total EU Spine Surgery Market, 2008-2017
Exhibit 3-44: EU Spine Surgery Market by Segment, in USD
Exhibit 3-45: EU Spine Surgery Market by Percentage and Segments, 2008
Exhibit 3-46: EU Spine Surgery Market Shares, 2008
Exhibit 3-47: United Kingdom: Total Spine Surgery Market, 2008-2017
Exhibit 3-48: United Kingdom: Total Spine Surgery Market, 2008-2017
Exhibit 3-49: UK: Total Spine Surgery Market Shares, 2008
Exhibit 3-50: France: Total Spine Surgery Market, 2008-2017
Exhibit 3-51: France: Total Spine Surgery Market, 2008-2017
Exhibit 3-52: France: Total Spine Surgery Market Shares, 2008
Exhibit 3-53: Germany: Total Spine Surgery Market, 2008-2017
Exhibit 3-54: Germany: Total Spine Surgery Market, 2008-2017
Exhibit 3-55: Germany: Total Spine Surgery Market Shares, 2008
Exhibit 3-56: Italy: Total Spine Surgery Market, 2008-2017
Exhibit 3-57: Italy: Total Spine Surgery Market, 2008-2017
Exhibit 3-58: Italy: Total Spine Surgery Market Shares, 2008
Exhibit 3-59: Total EU Spine Fusion and Fixation Market, 2008-2017
Exhibit 3-60: Total EU Spine Fusion and Fixation Market, 2008-2017
Exhibit 3-61: United Kingdom: Spinal Fusion and Fixation Market, 2008-2017
Exhibit 3-62: France: Spinal Fusion and Fixation Market, 2008-2017
Exhibit 3-63: Germany: Spinal Fusion and Fixation Market, 2008-2017
Exhibit 3-64: Italy: Spine Fusion and Fixation Market, 2008-2017
Exhibit 3-65: Total EU Non-Fusion Market, 2008-2017
Exhibit 3-66: Total EU Non-Fusion Market, 2008-2017
Exhibit 3-67: United Kingdom: Non-fusion Products Market, 2008-2017
Exhibit 3-68: France: Total Non-Fusion Products Market, 2008-2017
Exhibit 3-69: Germany: Total Non-fusion Market, 2008-2017
Exhibit 3-70: Italy: Non-fusion Products Market, 2008-2017
Exhibit 3-71: Total EU Disc Replacement Market, 2008-2017
Exhibit 3-72: Total EU Disc Replacement Market, 2008-2017
Exhibit 3-73: United Kingdom: Total Disc Replacement Market, 2008-2017
Exhibit 3-74: France: Total Disc Replacement Market, 2008-2017
Exhibit 3-75: Germany: Total Disc Replacement Market, 2008-2017
Exhibit 3-76: Italy: Total Disc Replacement Market, 2008-2017
Exhibit 3-77: Total EU Nucleus Replacement Market, 2008-2017
Exhibit 3-78: Total EU Nucleus Replacement Market, 2008-2017
Exhibit 3-79: United Kingdom: Nucleus Replacement Market, 2008-2017
Exhibit 3-80: France: Nucleus Replacement Market, 2008-2017
Exhibit 3-81: Germany: Nucleus Replacement Market, 2008-2017
Exhibit 3-82: Italy: Nucleus Replacement Market, 2008-2017
Exhibit 3-83: Total EU Interspinous Process Spacers (ISPs) Market, 2008-2017
Exhibit 3-84: Total EU Interspinous Process Spacers (ISPs) Market, 2008-2017
Exhibit 3-85: United Kingdom: Interspinous Process Spacers Market, 2008-2017
Exhibit 3-86: France: Interspinous Process Spacers Market, 2008-2017
Exhibit 3-87: Germany: Total Spine Surgery Market, 2008-2017
Exhibit 3-88: Italy: Interspinous Process Spacers Market, 2008-2017
Exhibit 3-89: Total EU Kyphoplasty Market, 2008-2017
Exhibit 3-90: Total EU Vertebroplasty/Kyphoplasty Market, 2008-2017
Exhibit 3-91: United Kingdom: Vertebroplasty/Kyphoplasty Market, 2008-2017
Exhibit 3-92: France: Vertebroplasty/Kyphoplasty Market, 2008-2017
Exhibit 3-93: Germany: Vertebroplasty/Kyphoplasty Market, 2008-2017
Exhibit 3-94: Italy: Vertebroplasty/Kyphoplasty Market, 2008-2017
Exhibit 3-95: EU Market for Computer Assisted Image Guided Surgery Products, 2008-2017
Exhibit 3-96: United Kingdom: Image Guided Surgery Market, 2008-2017
Exhibit 3-97: France: Image Guided Surgery Market, 2008-2017
Exhibit 3-98: Germany: Image Guided Surgery Market, 2008-2017
Exhibit 3-99: Italy: Image Guided Surgery Market, 2008-2017
Exhibit 3-100: Asia-Pacific: Total Spine Surgery Market, 2008-2017
Exhibit 3-101: Asia-Pacific: Total Spine Surgery Market, 2008-2017
Exhibit 3-102: Asia-Pacific: Spine Surgery Market Shares, 2008
Exhibit 3-103: Asia-Pacific: Spinal Fusion and Fixation Market, 2008-2017
Exhibit 3-104: Asia-Pacific: Spinal Fusion and Fixation Market, 2008-2017
Exhibit 3-105: Asia-Pacific: Non-fusion Products Market, 2008-2017
Exhibit 3-106: Asia-Pacific: Non-fusion Products Market, 2008-2017
Exhibit 3-107: Asia-Pacific: Spinal Fusion vs. Non Fusion Markets, 2008 vs. 2017
Exhibit 3-108: Asia-Pacific: Total Disc Replacement Market, 2008-2017
Exhibit 3-109: Asia-Pacific: Total Disc Replacement Market, 2008-2017
Exhibit 3-110: Asia-Pacific: Nucleus Replacement Market, 2008-2017
Exhibit 3-111: Asia-Pacific: Nucleus Replacement Market, 2008-2017
Exhibit 3-112: Asia-Pacific: Interspinous Processes Market, 2008-2017
Exhibit 3-113: Asia-Pacific: Interspinous Processes Market, 2008-2017
Exhibit 3-114: Asia-Pacific: Vertebroplasty/Kyphoplasty Market, 2008-2017
Exhibit 3-115: Asia-Pacific: Vertebroplasty/Kyphoplasty Market, 2008-2017
Exhibit 3-116: Asia-Pacific: Image Guided Surgery Market, 2008-2017
Exhibit 3-117: Asia-Pacific: Image Guided Surgery Market, 2008-2017
Exhibit 3-118: Rest of World Spine Surgery Market Shares, 2008
Exhibit 3-119: ROW, Spine Surgery Markets, 2008-2017
Exhibit 3-120: ROW, Spine Surgery Markets, 2008-2017
Exhibit 3-121: ROW: Fusion and Fixation Market, 2008-2017
Exhibit 3-122: ROW: Fusion and Fixation Market, 2008-2017
Exhibit 3-123: ROW: Non-Fusion Market, 2008-2017
Exhibit 3-124: ROW: Total Disc Replacement Market, 2008-2017
Exhibit 3-125: ROW: Nucleus Replacement Market, 2008-2017
Exhibit 3-126: ROW: Interspinous Process Spacers Market, 2008-2017
Exhibit 3-127: ROW: Vertebroplasty/Kyphoplasty Market, 2008-2017
Exhibit 3-128: ROW: Image-Guided Surgery Market, 2008-2017

Exhibit 4-1: CPT spinal fusion codes now allowed by CMS
Exhibit 4-2: BCBSNC coverage of bone morphogenetic protein
Exhibit 4-3: New CMS codes for spinal motion preservation
Exhibit 4-4: Summary of CMS Medicare cost data

For more information kindly visit
http://www.bharatbook.com/Market-Research-Reports/Spine-Surgery-Worldwide-2008-2017-Products-Technologies-Markets-and-Opportunities.html

This report is a detailed market and technology assessment and forecast of the products and technologies in the ablation market for treatment of soft tissues via energy-based modalities, including electrosurgery, radiosurgery, gamma knife, brachytherapy, cryogenic therapy, fluidjet therapy (hydrotherapy), microwave ablation, radiofrequency ablation, laser, thermal ablation, and ultrasonic ablation.

The report describes alternative energy-based technologies and the nature of their effect on soft tissue, the underlying basis of the technology, the requisite systems for their use (including capital equipment, devices and disposables), and their strengths and weaknesses for specific clinical applications. The report details current and anticipated target applications and assesses the current and forecast caseload for each energy-based therapeutic considering competition from any and all alternative energy-based or other therapeutics, with current and worldwide market forecasts (2008-2017) segmented by technology type and specific clinical segment. The report provides segmentation of the worldwide ablation market by both ablation technology and region/country: Americas (USA, Canada, Mexico, Brazil), Europe (Germany, United Kingdom, France, Italy, Spain, BeNeLux), Asia/Pacific (Japan, China, India, Australia) and Rest of World. The report details the current and emerging products, technologies and markets for each energy-based therapy. The report profiles over 60 key companies in this industry detailing their current products, current market position and products under development.

Table of Contents:

EXECUTIVE SUMMARY
Overview
Trends and Opportunities
Market Leaders

SECTION 1: ENERGY-BASED THERAPIES BY DISEASE STATE AND TECHNOLOGY
1.1 Cancer
1.1.1 Cryogenic therapy
1.1.2 Microwave therapy
1.1.3 Radiation therapy
1.1.4 Radiofrequency ablation
1.1.5 Stereotactic surgery
1.1.6 Thermal ablation
1.1.7 Laser ablation
1.1.8 Photodynamic therapy
1.1.9 Ultrasonic ablation
1.2 Cardiovascular disease
1.2.1 Angina pectoris
1.2.2 Atrial arrhythmias
1.2.2.1 Laser ablation
1.2.2.2 Cryoablation
1.2.2.3 Electrical cardioversion
1.2.2.4 Microwave ablation
1.2.2.5 RF ablation
1.2.3 Bradycardia
1.2.4 Critical ischaemia
1.2.5 Vascular occlusive disease
1.2.6 Ventricular arrhythmias
1.2.7 Wolf-Parkinson-White Disease
1.3 Elective surgery
1.3.1 Cosmetic surgery
1.3.1.1 Laser hair removal
1.3.1.2 Port wine stains
1.3.1.3 Psoriasis
1.3.1.4 Varicose veins
1.3.2 Ophthalmic surgery
1.3.2.1 Capsulotomy surgery
1.3.2.2 Laser in-situ keratomileusis (LASIK)
1.3.2.2.1 Wave-front guided laser in-situ keratomileusis
1.3.2.3 Laser epithelial keratomileusis (LASEK)
1.4 General surgery
1.4.1 Fecal incontinence
1.4.2 GERD
1.5 Gynecological applications
1.5.1 Hysterectomy
1.5.2 Menorrhagia
1.5.3 Bladder neck suspension
1.5.4 Fibroids
1.6 Urological applications
1.6.1 Urinary tract stones
1.6.2 Benign prostatic hypertrophy
1.6.2.1 TUMT
1.6.2.2 TUNA
1.6.2.3 Vaporization of the prostate (PVP)
1.6.2.4 Water-induced thermotherapy
1.7 Orthopedic applications
1.7.1 Capsular shrinkage
1.7.2 Carpal tunnel syndrome
1.7.3 Chondroplasty
1.7.4 Debridement
1.7.5 Epicondylitis and tendinitis
1.7.6 Inflammatory conditions
1.7.7 Nucleoplasty

Section 2: PRODUCTS AND TECHNOLOGIES
2.1 Cryogenic energy
2.2 Electrical energy
2.2.1 Implantable cardioverter defbibrillators
2.2.2 Resynchronisation systems
2.2.3 Pacing systems
2.2.4 Pain management
2.3 Hydromechanical energy
2.4 Light energy
2.4.1 Cold lasers
2.4.2 Excimer lasers
2.4.3 Photonic ablation
2.4.4 Ultraviolet B lasers
2.5 Microwave energy
2.6 Radiation energy
2.6.1 Brachytherapy
2.6.2 Radiosurgery
2.6.2.1 Cyberknife
2.6.2.2 Gamma knife
2.7 Radiofrequency energy
2.8 Thermal energy
2.9 Ultrasonic energy
2.9.2.1 Shock wave therapy
2.9.2.2 Ultrasonic surgical systems

Section 3: ABLATION TECHNOLOGIES MARKET
3.1 World market overview
3.2 Market segmentation by product type
3.3 Leading companies in global market
3.4 Major national markets
3.4.1 Americas
3.4.1.1 USA
3.4.1.2 Canada
3.4.1.3 Mexico
3.4.1.4 Brazil
3.4.2 Europe
3.4.2.1 Germany
3.4.2.2 United Kingdom
3.4.2.3 France
3.4.2.4 Italy
3.4.2.5 Spain
3.4.2.6 Benelux countries
3.4.3 Asia/Pacific
3.4.3.1 Japan
3.4.3.2 China
3.4.3.3 Australia
3.4.3.4 South Korea
3.4.3.5 India
3.4.4 Rest of world

Section 4: COMPANY PROFILES
4.1 The Industry
4.1.1 Abla-TX
4.1.1.1 Role in Cancer Treatment
4.1.2 Acoustic MedSystems
4.1.3 Accuray
4.1.4 ACMI/Gyrus/Olympus
4.1.5 AFx (Guidant)
4.1.6 Alcon
4.1.7 American Medical Systems
4.1.8 Angiodynamics
4.1.8.1 Financials
4.1.9 ArthroCare Corporation
4.1.10 AtriCure, Inc.
4.1.11 ATS Medical
4.1.11.1 Financial results
4.1.12 Bard EP
4.1.13 Bausch & Lomb (Warburg Pincus)
4.1.14 Baylis Medical Company
4.1.15 Biosense Webster
4.1.16 Biotronik Inc.
4.1.17 Biowave Corp
4.1.18 Boston Scientific Corp
4.1.18.1 Blazer Cardiac Ablation Catheters
4.1.18.2 Chilli Cooled Ablation Catheters
4.1.18.3 Steerocath-T Cardiac Ablation Catheter
4.1.18.4 Maestro
4.1.18.5 RF 3000® Radiofrequency Ablation System
4.1.18.6 Confient Implantable Cardioverter Defibrillator (ICD)
4.1.18.7 Financials
4.1.19 BSD Medical Corp.
4.1.19.1 MicroThermX-100 Microwave Ablation Systems
4.1.19.2 BSD500 Hyperthermia Systems
4.1.19.3 BSD2000 Hyperthermia Systems
4.1.20 Candela Corp.
4.1.21 Cardima Inc
4.1.22 CardioGenesis Corp
4.1.23 Celon AG
4.1.23.1 Surgery/Radiology
4.1.23.2 Phlebology
4.1.24 Celsion Corp.
4.1.25 ConMed Corp.
4.1.26 Covidien Ltd.
4.1.26.1 Vessel Sealing
4.1.26.2 Electrosurgery
4.1.26.3 Financial Results for fiscal 2007 and 2006
4.1.27 CryoCath
4.1.28 CryoCor, Inc.
4.1.29 CSA Medical Inc.
4.1.30 Cytyc Corp.
4.1.31 Dornier MedTech
4.1.31.1 Compact Delta II
4.1.31.2 Compact Delta II UIMS
4.1.31.3 Compact Sigma
4.1.31.4 Lithotripter S II
4.1.31.5 Medilas D MultiBeam
4.1.31.6 Medilas D FlexiPulse
4.1.31.7 Medilas H 20
4.1.32 EDAP TMS S.A.
4.1.32.1 Financial Update
4.1.33 Elekta
4.1.33.1 Leksell Gamma Knife 4
4.1.33.2 Leksell Gamma Knife 4C
4.1.33.3 Leksell Gamma Knife Perfexion
4.1.34 Endocare (merged with Galil Medical)
4.1.35 Erbe
4.1.35.1 Electrosurgery
4.1.35.2 Water Jet Surgery
4.1.35.3 Cryosurgery
4.1.36 Ethicon Endo-Surgery Inc.
4.1.37 Galil Medical (merged with Endocare)
4.1.38 Getinge Group
4.1.38.1 Cardiac Surgery
4.1.38.2 Vascular Surgery
4.1.39 HealthTronics Surgical Services
4.1.39.1 Medical Products
4.1.39.2 Urology Services
4.1.40 Medtronic
4.1.40.1 Cardiac Rhythm Disease Management (CRDM)
4.1.40.2 Bradycardia
4.1.40.3 Tachyarrhythmia
4.1.40.4 Ablation Catheters
4.1.41 MedWaves Inc.
4.1.42 Mirabilis Medica
4.1.43 Misonix Inc.
4.1.43.1 Sonablate
4.1.44 NeuWave Medical Inc.
4.1.45 Olympus Medical
4.1.46 OmniSonics Medical Technologies Inc. — filed for Chapter 7 bankruptcy in March 2009
4.1.47 PhotoMedex Inc.
4.1.48 PhotoTherapeutics Inc.
4.1.49 PhotoThera Inc.
4.1.50 RFA Medical Inc.
4.1.51 Smith & Nephew
4.1.51.1 Financial Results
4.1.52 Spectranetics
4.1.53 St Jude Medical Inc.
4.1.53.1 Products for Cardiac Rhythm Management
4.1.53.2 Atrial Fibrillation
4.1.53.3 Advanced Neuromodulation Systems
4.1.54 Starion Instruments
4.1.55 Stereotaxis Inc.
4.1.55.1 Stereotaxis Magnetic Navigation System
4.1.56 Theragenics Corporation
4.1.57 Urologix Inc
4.1.57.1 Targis System
4.1.58 USHIFU
4.1.59 Varian Medical Systems Inc.
4.1.59.1 RapidArc
4.1.59.2 Dynamic Targeting Image-Guided Radiation Therapy (IGRT)
4.1.59.3 SmartBeam IMRT
4.1.59.4 Dynamic Adaptive Radiotherapy (DART)
4.1.59.5 IGBT - Image-Guided Brachytherapy
4.1.59.6 Varian Proton Therapy System
4.1.60 VNUS Medical Technologies, Inc.
4.1.60.1 ClosureFAST System
4.1.60.2 Model RFG2 Advanced Radiofrequency Generator
4.1.60.3 Quarterly Financials
APPENDIX: COMPANY DETAILS

List of Exhibits

Exhibit ES-1: Overview of the Global Ablation and Other Energy-Based Therapies Market by Modality
Exhibit ES-2: Growth of the Worldwide Ablation and Other Energy-Based Therapies Market by Modality
Exhibit ES-3: Worldwide Ablation and Other Energy-Based Therapies Market by Clinical Application
Exhibit ES-4: Market Leaders in Energy-Based Therapies

Exhibit 1-1: Energy-Based Treatment Options for Prostate Cancer
Exhibit 1-2: Energy-Based Therapies for Cardiovascular Diseases
Exhibit 1-3: Energy-based Therapies for Atrial Arrhythmias
Exhibit 1-4: Ventricular Arrhythmia Therapies
Exhibit 1-5: Energy-based Implants for Ventricular Arrhythmias
Exhibit 1-6: Cosmetic Lasers
Exhibit 1-7: Traditional LAVH vs PK LVAH
Exhibit 1-8: Orthopedic Application of Electrosurgical Devices
Exhibit 1-9: Collagen Types
Exhibit 1-10: Chondroplasty Systems’ Zone of Thermal Damage

Exhibit 2-1: Energy-Based Technologies
Exhibit 2-2: Cryogenic-Energy Ablation Products
Exhibit 2-3: Electrical-Energy Ablation Products
Exhibit 2-4: Hydromechanical Ablation Products
Exhibit 2-5: Light-Energy Ablation Products
Exhibit 2-6: Microwave Ablation Products
Exhibit 2-7: Radiation-Energy Ablation Products
Exhibit 2-8: Radioactive Seed Products for Brachytherapy
Exhibit 2-9: Radiofrequency (RF) Ablation Products
Exhibit 2-10: Thermal-Energy Ablation Products
Exhibit 2-11: Ultrasound Ablation Products
Exhibit 2-12: High Growth Applications of Ultrasonic Surgical Systems

Exhibit 3-1: World Medical Device Market, by Region, 2008
Exhibit 3-2: World Energy-based Device Market by Product Category, 2007
Exhibit 3-3: Overview of the Energy-Based Therapies Market by Clinical Application
Exhibit 3-4: Arrhythmias Treated with Ablation Therapy
Exhibit 3-5: 25-Year Changes in National Mortality Rates Due to Ischaemic Heart Disease
Exhibit 3-6: Cardiac Angioplasty Procedures Per 100,000 Population, By Country in 2000
Exhibit 3-7: Cardiac Dysrhythmias and Related Conditions
Exhibit 3-8: Solid cancers: Ablation Market Potential
Exhibit 3-9: World Age-Standardize Cancer Incidence per 100, 000 Population (All Ages), by Cancer Type
Exhibit 3-10: Global Energy-based Therapies Market, by Product Category
Exhibit 3-11: World Energy-based Device Market by Product Category, 2007 and 2017
Exhibit 3-12: Ablation and Energy-based Therapeutic Companies by Product Area, Indication and Market Shares, Worldwide, 2008
Exhibit 3-13: Ablation Market Revenues ($millions), Americas, by Country, 2007-2017
Exhibit 3-14: Ablation Market Revenues ($000s) US, by Product Segment, 2007-2017
Exhibit 3-15: Ablation Market Revenues ($000s), Canada, by Product Segment, 2007-2017
Exhibit 3-16: Ablation Market Revenues ($000s), Brazil, by Product Segment, 2007-2017
Exhibit 3-17: Ablation Market Revenues ($000s), Mexico, by Product Segment, 2007-2017
Exhibit 3-18: Ablation Market Revenues ($millions), Europe, by Country, 2007-2017
Exhibit 3-19: Ablation Market Revenues ($000s), Germany, by Product Segment, 2007-2017
Exhibit 3-20: Ablation Market Revenues ($000s), United Kingdom, by Product Segment, 2007-2017
Exhibit 3-21: Ablation Market Revenues ($000s), France, by Product Segment, 2007-2017
Exhibit 3-22: Ablation Market Revenues ($000s), Italy, by Product Segment, 2007-2017
Exhibit 3-23: Ablation Market Revenues ($000s), Spain, by Product Segment, 2007-2017
Exhibit 3-24: Ablation Market Revenues ($000s), BeNeLux, by Product Segment, 2007-2017
Exhibit 3-25: Ablation Market Revenues ($millions), Asia/Pacific, by Country, 2007-2017
Exhibit 3-26: Ablation Market Revenues ($000s), Japan, by Product Segment, 2007-2017
Exhibit 3-27: Ablation Market Revenues ($000s), China, by Product Segment, 2007-2017
Exhibit 3-28: Ablation Market Revenues ($000s), India, by Product Segment, 2007-2017
Exhibit 3-29: Ablation Market Revenues ($000s), Australia, by Product Segment, 2007-2017
Exhibit 3-30: Ablation Market Revenues ($millions), Rest of World, 2007-2017
Exhibit 3-31: Ablation Market Revenues ($000s), Rest of World, by Product Segment, 2007-2017

Exhibit 4-1: M&A Activity Among Energy-based Companies
Exhibit 4-2: AngioDynamics Financial Figures for Fiscal 2007 and 2006
Exhibit 4-3: ATS Financial Results for Q2 2008 and 2007
Exhibit 4-4: Boston Scientific Financials, Three Months Ended June 30, 2007 & 2008
Exhibit 4-5: CardioGenesis Financial Data, 2006 &2007
Exhibit 4-6: Covidien Ltd Financial Results, 2006 & 2007
Exhibit 4-7: Covidien Medical Device sales by Product Group
Exhibit 4-8: EDAP TMS Financial Results, 1st Quarter 2008 (to March 31st)
Exhibit 4-9: Endocare Quarterly Results, 2007 & 2008
Exhibit 4-10: Medtronic Revenues, 2007
Exhibit 4-11: Six-month Financial Data for Smith & Nephew, 2007 & 2008
Exhibit 4-12: TheraGenics Financial Results, Fourth Quarter 2007 and Full Year
Exhibit 4-13: Varian Medical Systems, Financial Summary, 2005-2007

For more information kindly visit
http://www.bharatbook.com/Market-Research-Reports/Ablation-Technologies-Worldwide-Market-2008-2017-Products-Technologies-Markets-Companies-and-Opportunities.html

This report details the complete range of sealants & glues technologies used in traumatic, surgical and other wound closure, from tapes, sutures and staples to hemostats, fibrin sealants/glues and medical adhesives. The report details current clinical and technology developments in this huge and rapidly growing worldwide market, with data on products in development and on the market; market size and forecast; competitor market shares; competitor profiles; and market opportunity.

This report is a market and technology assessment and forecast of surgical sealants, glues, hemostasis, other wound closure and anti-adhesion. The report details the current and emerging products, technologies and markets involved in wound closure and sealing using sutures and staples, tapes, hemostats, fibrin and sealant products, medical adhesives and products to prevent surgical adhesions. The report provides a worldwide current and annual forecast to 2013 of the markets for these technologies, with particular emphasis on the market impact of new technologies through the coming decade. The report provides specific forecasts and shares of the worldwide market by segment for the U.S., Europe (United Kingdom, German, France, Italy, BeNeLux), Latin America, Japan and Rest of World.

The report provides background data on the surgical, disease and traumatic wound patient populations targeted by current technologies and those under development, and the current clinical practices in the management of these patients, including the dynamics among the various clinical specialties or subspecialties vying for patient population and facilitating or limiting the growth of technologies.

The report establishes the current worldwide market size for major technology segments as a baseline for and projecting growth in the market over a ten-year forecast. The report also assesses and projects the composition of the market as technologies gain or lose relative market performance over this period.

For more information kindly visit
http://www.bharatbook.com/Market-Research-Reports/Worldwide-Surgical-Sealants-Glues-Wound-Closure-and-Anti-Adhesion-Markets-2009-2013.html

This report details the complete range of products and technologies in spine surgery, including the surgical management of spine disorders, diseases and trauma, with treatments including use of grafts, demineralized bone, fusion, stabilization, disc replacement, nucleus replacement, vertebroplasty, kyphoplasty, imaging, minimally invasive surgical technologies, energy-based therapies and biologics. The report details current clinical and technology developments in the huge and rapidly growing spine surgery technologies worldwide market, with data on products in development and on the market; market size and forecast; competitor market shares; competitor profiles; and market opportunity.

This report is a detailed market and technology assessment and forecast of the products and technologies in the management of diseases and disorders of the spine. The report describes diseases and disorders of the spine, encompassing congenital disorders, inflammatory and infectious diseases; degenerative diseases; herniations, stenoses, myelopathies and other “mechanical” disorders of the spine; spinal trauma; tumors of the spine; and others. The report characterizes the patient populations, their current clinical management, and trends in clinical management as new techniques and technologies are expected to be developed and emerge. The report details the currently available products and technologies, and manufacturer offerings. The report details products and technologies under development and markets for each in spine surgery. The report provides a current and forecast assessment of the worldwide markets for these technologies, with geographic segmentation by U.S. & Canada, European Union (detailing France, United Kingdom, Germany, Italy and Spain), Japan and Rest of World. The report provides emphasis on the market impact of new technologies through the coming decade, profiling nearly 100 active companies in this industry, with comprehensive detail on key companies, providing data on their current products, current market position and products under development.

Table of Contents:

Executive Summary
Non-fusion products
Disc arthroplasty (total disc replacement)
Nuclear arthroplasty
European Union
Asia-Pacific
Rest of World
Selected company-related events
Medtronic
LDR Spine
Synthes Spine
Disc Motion Technologies
Spine Structure
Products and technologies
CMS, carriers reverse decision on artificial discs
Cost effectiveness

Section 1:          The Spine: Structure, Disorders, Treatment
1.1         Overview: Spine Structure
1.2         Diseases and disorders of the spine
1.2.1             Congenital Disorders
1.2.2             Inflammatory and Infectious Diseases of the Spine
1.2.3             Degenerative Diseases of the Spine
1.2.4             Mechanical Disorders of the Spine
1.2.5             Spinal Trauma
1.2.6             Tumors of the Spine
1.3         Spine management
1.3.1             Clinical: the SPORT Study
1.3.2             Diagnostic studies
1.3.3             Surgical procedures of the spine
1.3.4             Minimally Invasive Procedures
1.3.5             Minimally Invasive Bone Grafting Procedures
1.3.6             Acupuncture for treatment of chronic low back pain

Section 2:          Products and Technologies
2.1         Bone grafts and bone graft substitutes
2.2         Demineralized bone matrix (DBM)
2.2.1             Particle based DBM
2.2.2             Biomimetic matrix bone substitute
2.2.3             Bone morphogenic proteins (BMPs)
2.3         Spinal fusion and fixation products and technologies
2.3.1             Spine surgery instrumentation
2.3.2             Cervical fusion devices
2.3.3             Interbody fusion devices
2.3.4             Posterior dynamic stabilization systems
2.4         Non-fusion products and technologies
2.4.1             Disc arthroplasty
2.4.2             Nuclear arthroplasty and nuclear disc prostheses
2.4.3             Facet repair and replacement
2.5         Vertebroplasty and kyphoplasty
2.5.1             Vertebral compression fracture treatment technologies
2.6         Advances in spinal image-guided surgery
2.6.1             Medtronic’s StealthStation
2.6.2             GE Healthcare’s Fluoro-Spine
2.6.3             Elekta’s Axesse system
2.6.4             Zimmer’s ORTHOsoft Navitrack® FluoroSpine® System
2.7         Products and technologies for minimally invasive spinal surgery
2.7.1             ArthroCare’s spineWand
2.7.2             Medtronic’s MAST™ portfolio
2.7.3             NuVasive’s Maximum Access Surgery (MAS)
2.7.4             Abbott Spine’s Harmony Retractor
2.7.5             Globus transforaminal TDR device
2.8         Energy-based therapies
2.8.1             Bone growth stimulators
2.8.2             Intradiscal Electrothermal Therapy (IDET)
2.9         Biologics

Section 3:          Market Size, Forecast and Competitor Shares
3.1         Global market size, forecast and competitor shares
3.2         USA & Canada
3.2.1             Bone grafts and bone graft substitutes
3.2.2             Spinal fusion and fixation products
3.2.3             Non-fusion products
3.2.4             Vertebroplasty and Kyphoplasty
3.2.5             Interspinous process spacers (ISP)
3.2.6             Computer assisted image guided surgery products
3.3         European Union
3.3.1             United Kingdom
3.3.2             France
3.3.3             Germany
3.3.4             Italy
3.3.5             Spinal fusion and fixation products
3.3.6             Non-fusion products
3.3.7             Total disc replacement
3.3.8             Nucleus replacement
3.3.9             Interspinous process spacers (ISPs)
3.3.10           Kyphoplasty
3.3.11           Image Guided Surgery Products Market
3.4         Asia-Pacific
3.4.1             Spinal fusion and fixation products
3.4.2             Non-fusion products
3.4.3             Image guided surgery products
3.5         Rest of World

Section 4:          Regulatory, Cost and Reimbursement Issues
4.1         Regulatory Issues Associated with Spine Treatments, Materials and Methods
4.1.1             Regulatory issues regarding off-label usage
4.1.2             Changes to European Device Safety Regulations
4.1.3             NICE and dynamic stabilization procedures
4.2         Reimbursement Developments
4.2.1             CMS, carriers reverse decision on artificial discs
4.2.2             CMS reverses stand on two spinal fusion procedures
4.2.3             ArthroCare and DiscoCare
4.2.4             Bone growth factor reimbursement issues
4.2.5             CMS investigates Thermal Intradiscal Therapy
4.2.6             CMS announces new ICD-9-CM spinal procedure codes
4.2.7             Wellmark and energy-based treatments
4.3         Cost effectiveness

Section 5:          Company Profiles
5.1         Abbott Spine
5.2         AlloSource
5.3         Alphatec Holdings, Inc.
5.4         Altiva Corporation
5.5         Anulex Technologies, Inc.
5.6         ApaTech
5.7         Applied Spine Technologies
5.8         ArthroCare Corporation
5.9         A-Spine Holding Group Corporation
5.10       Axial Biotech
5.11       AxioMed Spine Corporation
5.12       B. Braun/Aesculap, Inc.
5.13       BioAssets Development Corporation
5.14       Biomet
5.15       Biorthex, Inc.
5.16       Blackstone Medical, Inc
5.17       BrainLAB
5.18       Cardinal Health
5.19       Cervitech
5.20       Changzhou Kanghui
5.21       Co.Don AG
5.22       CoLigne AG
5.23       Cook Group
5.24       CoreSpine Technologies LLC
5.25       Corin Group
5.26       Cortek, Inc
5.27       Cryolife, Inc.
5.28       Cyberkinetics Neurotechnology Systems
5.29       Cytori Therapeutics
5.30       DePuy Spine/J&J
5.31       Disc Dynamics
5.32       Disc Motion Technologies
5.33       Encore Medical Corporation / DJO Surgical (ReAble Therapeutics)
5.34       Facet Solutions
5.35       Fixano (Small Bone Innovations)
5.36       GE Healthcare
5.37       Gentis, Inc
5.38       Globus Medical
5.39       GMReis
5.40       HydroCision
5.41       [Innovative Spinal Technologies — ceased operations January 2009]
5.42       Integra LifeSciences
5.43       Integra Radionics
5.44       Interpore Cross
5.45       Interventional Spine
5.46       Invibio
5.47       LDR Holding Corporation
5.48       LifeNet Health, Inc.
5.49       Mazor Surgical Technologies Ltd
5.50       Medtronic, Inc
5.51       Medtronic Sofamor Danek
5.52       Medtronic Surgical Navigation
5.53       Mekanika, Inc.
5.54       Merck & Co., Inc.
5.55       MiMedx
5.56       Misonix
5.57       MTF (Musculoskeletal Transplant Foundation)
5.58       NPS Pharmaceuticals
5.59       N Spine, Inc. (Synthes)
5.60       NuVasive, Inc.
5.61       Ortho Development Corporation
5.62       Orthofix International, N.V.
5.63       OrthoVita
5.64       Osiris Therapeutics
5.65       Osteotech, Inc.
5.66       Ortosintese
5.67       Paradigm Spine, LLC
5.68       Pitkar
5.69       Praxim
5.70       Ranier Technology Limited
5.71       Raymedica, Inc.
5.72       Regeneration Technologies, Inc
5.73       Scient’X
5.74       SeaSpine, Inc.
5.75       Sharma Surgical
5.76       Small Bone Innovations, LLC
5.77       Smart Disc
5.78       Smith & Nephew
5.79       SpinalMotion
5.80       SpineMedica Corporation
5.81       Spineology
5.82       SpineOvations
5.83       SpineVision Inc
5.84       Spine Wave, Inc.
5.85       Stryker Corporation
5.86       Stryker Instruments
5.87       Stryker Spine
5.88       Synthes Spine Solutions
5.89       Theken Spine
5.90       TranS1, Inc.
5.91       Trimedyne, Inc.
5.92       Ulrich Medical GmbH
5.93       Valleylab
5.94       Vertebron Inc.
5.95       Waston Medical
5.96       Wright Medical Technology
5.97       X-spine Systems, Inc.
5.98       Zimmer Spine
Appendix:  Company Directory

List of Exhibits

Exhibit ES-1: Total Global Spine Surgery Market, 2008-2017
Exhibit ES-2: Total Global Spine Surgery Market, 2008-2017
Exhibit ES-3: Global Spine Surgery Market by Segment, in USD Terms
Exhibit ES-4: Global Spine Surgery Market by Percentage and Segments, 2008
Exhibit ES-5: Major Spine Market Segments, 2008-2017
Exhibit ES-6: Key Factors Driving Growth in the Global Spine Surgery Market
Exhibit ES-7: Global Spine Surgery Market Shares, 2008
Exhibit ES-8: US & Canadian Market for Spine Surgery Devices
Exhibit ES-9: US Company Market Shares for Spine Surgery Devices, 2008
Exhibit ES-10: Total Global Spine Surgery Market, by Region, 2008
Exhibit ES-11: Total EU Spine Surgery Market, 2008-2017
Exhibit ES-12: Total EU Spine Surgery Market, 2008-2017
Exhibit ES-13: EU Spine Surgery Market Shares, 2008
Exhibit ES-14: Asia-Pacific: Total Spine Surgery Market, 2008-2017
Exhibit ES-15: Asia-Pacific: Total Spine Surgery Market, 2008-2017
Exhibit ES-16: Asia-Pacific: Spine Surgery Market Shares, 2008
Exhibit ES-17: Rest of World Spine Surgery Market Shares, 2008
Exhibit ES-18: ROW, Spine Surgery Markets, 2008-2017
Exhibit ES-19: Lateral and Posterior Views of the Spine
Exhibit ES-20: Human Spine Structure Showing Vertebrae, Intervertebral Discs, and Spinal Cord
Exhibit ES-21: US Census figures and projections, ages 65 and up, 1900-2050.
Exhibit ES-22: Number & Percentage of U.S. Population over Age 65, 1910–2050
Exhibit ES-23: Mechanical Disorders of the Spine
Exhibit ES-24: Start-up companies and areas of interest
Exhibit ES-25: CPT spinal fusion codes now allowed by CMS
Exhibit ES-26: Summary of CMS Medicare cost data

Exhibit 1-1: Lateral and Posterior Views of the Spine
Exhibit 1-2: Human Spine Structure Showing Vertebrae, Intervertebral Discs, and Spinal Cord
Exhibit 1-3: Components of the Human Spine
Exhibit 1-4: US Census figures and projections, ages 65 and up, 1900-2050.
Exhibit 1-5: Number & Percentage of U.S. Population over Age 65, 1910–2050
Exhibit 1-6: Congenital Disorders of the Spine
Exhibit 1-7: Inflammatory and Infectious Diseases of the Spine
Exhibit 1-8: Degenerative Diseases of the Spine
Exhibit 1-9: Estimated Annual Number of Fractures Due to Osteoporosis in the U.S. (Total: Over 1.5 Million)
Exhibit 1-10: Mechanical Disorders of the Spine
Exhibit 1-11: Location, Effects, and Incidence of Major Lumbar Disc Herniations
Exhibit 1-12: Clinical Features—Radiculopathy by Spinal Level
Exhibit 1-13: Causes of Trauma to Spinal Regions
Exhibit 1-14: Tumors of the Spine
Exhibit 1-15: Traditional (“Open”) Spinal Procedures
Exhibit 1-16: Estimated Number of Spinal Fusion Procedures Performed in the U.S., 2005–2015
Exhibit 1-17: Minimally Invasive Spinal Procedures

Exhibit 2-1: Spinal Allografts: Vendors and Products
Exhibit 2-2: Hydroxyapatite Bone Substitutes: Vendors, Products
Exhibit 2-3: Bone growth stimulatory proteins, peptides and devices
Exhibit 2-4: Fusion instrumentation companies
Exhibit 2-5: Developers of Interspinous Process Spacers
Exhibit 2-6: Developers of Total Disc Replacements
Exhibit 2-7: Artificial Cervical Discs Currently in US Clinical Trials
Exhibit 2-8: Artificial Cervical Discs Currently Available in the EU
Exhibit 2-9: Total disc replacement devices
Exhibit 2-10: Developers of Prosthetic Disc Nuclei
Exhibit 2-11: Nucleus replacement implants
Exhibit 2-12: Current nucleus arthroplasty motion preservation IDE pilot studies
Exhibit 2-13: Bone growth stimulatory proteins, peptides and devices
Exhibit 2-14: Cellular therapies: manufacturers and product
Exhibit 2-15: Other start-up companies and areas of interest

Exhibit 3-1: Total Global Spine Surgery Market, 2008-2017
Exhibit 3-2: Total Global Spine Surgery Market, 2008-2017
Exhibit 3-3: Global Spine Surgery Market by Segment, in USD Terms
Exhibit 3-4: Global Spine Surgery Market by Percentage and Segments, 2008
Exhibit 3-5: Key Factors Driving Growth in the Global Spine Surgery Market
Exhibit 3-6: Major Spine Market Segments, 2008-2017
Exhibit 3-7: Global Spine Surgery Market Shares, 2008
Exhibit 3-8: US & Canadian Market for Spine Surgery Devices
Exhibit 3-9: US & Canadian Market for Spine Surgery Devices
Exhibit 3-10: US Company Market Shares for Spine Surgery Devices, 2008
Exhibit 3-11: Usage of Bone Grafts and Bone Graft Substitutes in Spinal Fusion Procedures (excluding BMPs)
Exhibit 3-12: US Market for Bone Graft Substitutes
Exhibit 3-13: US Market for Spine-Related Orthobiologics, 2008-2017
Exhibit 3-14: US & Canadian Market for Spinal Fusion and Fixation Devices
Exhibit 3-14B:  US & Canadian Spinal Fusion Procedures by Segment (Cervical, Lumbar, Thoracic), 2008-2017
Exhibit 3-15: Number of Spinal Fusions
Exhibit 3-16: US & Canadian Market for Spinal Fusion and Fixation Devices
Exhibit 3-17: US Market Shares, Spinal Fusion and Fixation Devices, 2008
Exhibit 3-18: US Market Shares, Spinal Fusion and Fixation Devices, 2008
Exhibit 3-19 Total US Non-Fusion Device Market
Exhibit 3-20: Total US Non-Fusion Device Market
Exhibit 3-21: US Annulus Repair Market, 2009-2015
Exhibit 3-22: US Annulus Repair Market, 2009-2015
Exhibit 3-23: Total Market for Disc Arthroplasty (Cervical Plus Thoracolumbar)
Exhibit 3-24: US Market for Cervical Disc Replacement
Exhibit 3-25: US Market for Cervical Disc Replacement
Exhibit 3-26: US Market for Thoracolumbar Disc Replacement
Exhibit 3-27: US Market for Thoracolumbar Disc Replacement
Exhibit 3-28: US & Canadian Markets for Nuclear Arthroplasty
Exhibit 3-29: US Market for Nucleus Replacement
Exhibit 3-30: Total US Market for Vertebroplasty and Kyphoplasty
Exhibit 3-31: US Market for Vertebroplasty
Exhibit 3-32: US Market for Vertebroplasty
Exhibit 3-33: US Market for Kyphoplasty
Exhibit 3-34: US Market for Kyphoplasty
Exhibit 3-35: 2008 US Market Shares, Combined Vertebroplasty/Kyphoplasty
Exhibit 3-36: US Interspinous Process Spacers Market, 2008-2017
Exhibit 3-37: US Interspinous Process Spacers Market, 2008-2017
Exhibit 3-38: US Market for Image Guided Surgery Devices
Exhibit 3-39: US Market for Image Guided Surgery Devices
Exhibit 3-40: US Competitor Shares, Image Guided Surgery Devices, 2008
Exhibit 3-41: Total Global Spine Surgery Market, by Region, 2008
Exhibit 3-42: Total EU Spine Surgery Market, 2008-2017
Exhibit 3-43: Total EU Spine Surgery Market, 2008-2017
Exhibit 3-44: EU Spine Surgery Market by Segment, in USD
Exhibit 3-45: EU Spine Surgery Market by Percentage and Segments, 2008
Exhibit 3-46: EU Spine Surgery Market Shares, 2008
Exhibit 3-47: United Kingdom: Total Spine Surgery Market, 2008-2017
Exhibit 3-48: United Kingdom: Total Spine Surgery Market, 2008-2017
Exhibit 3-49: UK: Total Spine Surgery Market Shares, 2008
Exhibit 3-50: France: Total Spine Surgery Market, 2008-2017
Exhibit 3-51: France: Total Spine Surgery Market, 2008-2017
Exhibit 3-52: France: Total Spine Surgery Market Shares, 2008
Exhibit 3-53: Germany: Total Spine Surgery Market, 2008-2017
Exhibit 3-54: Germany: Total Spine Surgery Market, 2008-2017
Exhibit 3-55: Germany: Total Spine Surgery Market Shares, 2008
Exhibit 3-56: Italy: Total Spine Surgery Market, 2008-2017
Exhibit 3-57: Italy: Total Spine Surgery Market, 2008-2017
Exhibit 3-58: Italy: Total Spine Surgery Market Shares, 2008
Exhibit 3-59: Total EU Spine Fusion and Fixation Market, 2008-2017
Exhibit 3-60: Total EU Spine Fusion and Fixation Market, 2008-2017
Exhibit 3-61: United Kingdom: Spinal Fusion and Fixation Market, 2008-2017
Exhibit 3-62: France: Spinal Fusion and Fixation Market, 2008-2017
Exhibit 3-63: Germany: Spinal Fusion and Fixation Market, 2008-2017
Exhibit 3-64: Italy: Spine Fusion and Fixation Market, 2008-2017
Exhibit 3-65: Total EU Non-Fusion Market, 2008-2017
Exhibit 3-66: Total EU Non-Fusion Market, 2008-2017
Exhibit 3-67: United Kingdom: Non-fusion Products Market, 2008-2017
Exhibit 3-68: France: Total Non-Fusion Products Market, 2008-2017
Exhibit 3-69: Germany: Total Non-fusion Market, 2008-2017
Exhibit 3-70: Italy: Non-fusion Products Market, 2008-2017
Exhibit 3-71: Total EU Disc Replacement Market, 2008-2017
Exhibit 3-72: Total EU Disc Replacement Market, 2008-2017
Exhibit 3-73: United Kingdom: Total Disc Replacement Market, 2008-2017
Exhibit 3-74: France: Total Disc Replacement Market, 2008-2017
Exhibit 3-75: Germany: Total Disc Replacement Market, 2008-2017
Exhibit 3-76: Italy: Total Disc Replacement Market, 2008-2017
Exhibit 3-77: Total EU Nucleus Replacement Market, 2008-2017
Exhibit 3-78: Total EU Nucleus Replacement Market, 2008-2017
Exhibit 3-79: United Kingdom: Nucleus Replacement Market, 2008-2017
Exhibit 3-80: France: Nucleus Replacement Market, 2008-2017
Exhibit 3-81: Germany: Nucleus Replacement Market, 2008-2017
Exhibit 3-82: Italy: Nucleus Replacement Market, 2008-2017
Exhibit 3-83: Total EU Interspinous Process Spacers (ISPs) Market, 2008-2017
Exhibit 3-84: Total EU Interspinous Process Spacers (ISPs) Market, 2008-2017
Exhibit 3-85: United Kingdom: Interspinous Process Spacers Market, 2008-2017
Exhibit 3-86: France: Interspinous Process Spacers Market, 2008-2017
Exhibit 3-87: Germany: Total Spine Surgery Market, 2008-2017
Exhibit 3-88: Italy: Interspinous Process Spacers Market, 2008-2017
Exhibit 3-89: Total EU Kyphoplasty Market, 2008-2017
Exhibit 3-90: Total EU Vertebroplasty/Kyphoplasty Market, 2008-2017
Exhibit 3-91: United Kingdom: Vertebroplasty/Kyphoplasty Market, 2008-2017
Exhibit 3-92: France: Vertebroplasty/Kyphoplasty Market, 2008-2017
Exhibit 3-93: Germany: Vertebroplasty/Kyphoplasty Market, 2008-2017
Exhibit 3-94: Italy: Vertebroplasty/Kyphoplasty Market, 2008-2017
Exhibit 3-95: EU Market for Computer Assisted Image Guided Surgery Products, 2008-2017
Exhibit 3-96: United Kingdom: Image Guided Surgery Market, 2008-2017
Exhibit 3-97: France: Image Guided Surgery Market, 2008-2017
Exhibit 3-98: Germany: Image Guided Surgery Market, 2008-2017
Exhibit 3-99: Italy: Image Guided Surgery Market, 2008-2017
Exhibit 3-100: Asia-Pacific: Total Spine Surgery Market, 2008-2017
Exhibit 3-101: Asia-Pacific: Total Spine Surgery Market, 2008-2017
Exhibit 3-102: Asia-Pacific: Spine Surgery Market Shares, 2008
Exhibit 3-103: Asia-Pacific: Spinal Fusion and Fixation Market, 2008-2017
Exhibit 3-104: Asia-Pacific: Spinal Fusion and Fixation Market, 2008-2017
Exhibit 3-105: Asia-Pacific: Non-fusion Products Market, 2008-2017
Exhibit 3-106: Asia-Pacific: Non-fusion Products Market, 2008-2017
Exhibit 3-107: Asia-Pacific: Spinal Fusion vs. Non Fusion Markets, 2008 vs. 2017
Exhibit 3-108: Asia-Pacific: Total Disc Replacement Market, 2008-2017
Exhibit 3-109: Asia-Pacific: Total Disc Replacement Market, 2008-2017
Exhibit 3-110: Asia-Pacific: Nucleus Replacement Market, 2008-2017
Exhibit 3-111: Asia-Pacific: Nucleus Replacement Market, 2008-2017
Exhibit 3-112: Asia-Pacific: Interspinous Processes Market, 2008-2017
Exhibit 3-113: Asia-Pacific: Interspinous Processes Market, 2008-2017
Exhibit 3-114: Asia-Pacific: Vertebroplasty/Kyphoplasty Market, 2008-2017
Exhibit 3-115: Asia-Pacific: Vertebroplasty/Kyphoplasty Market, 2008-2017
Exhibit 3-116: Asia-Pacific: Image Guided Surgery Market, 2008-2017
Exhibit 3-117: Asia-Pacific: Image Guided Surgery Market, 2008-2017
Exhibit 3-118: Rest of World Spine Surgery Market Shares, 2008
Exhibit 3-119: ROW, Spine Surgery Markets, 2008-2017
Exhibit 3-120: ROW, Spine Surgery Markets, 2008-2017
Exhibit 3-121: ROW: Fusion and Fixation Market, 2008-2017
Exhibit 3-122: ROW: Fusion and Fixation Market, 2008-2017
Exhibit 3-123: ROW: Non-Fusion Market, 2008-2017
Exhibit 3-124: ROW: Total Disc Replacement Market, 2008-2017
Exhibit 3-125: ROW: Nucleus Replacement Market, 2008-2017
Exhibit 3-126: ROW: Interspinous Process Spacers Market, 2008-2017
Exhibit 3-127: ROW: Vertebroplasty/Kyphoplasty Market, 2008-2017
Exhibit 3-128: ROW: Image-Guided Surgery Market, 2008-2017

Exhibit 4-1: CPT spinal fusion codes now allowed by CMS
Exhibit 4-2: BCBSNC coverage of bone morphogenetic protein
Exhibit 4-3: New CMS codes for spinal motion preservation
Exhibit 4-4: Summary of CMS Medicare cost data

For more information kindly visit
http://www.bharatbook.com/Market-Research-Reports/Spine-Surgery-Worldwide-2008-2017-Products-Technologies-Markets-and-Opportunities.html

Worldwide Market for Drug-Eluting, Bare and Other Coronary Stents, 2008-2017

This report details the worldwide market for the use of alternative stent devices in the treatment of coronary artery disease. The report assesses the treatment of coronary artery disease by alternative treatment methodologies (percutaneous intervention with or without stenting, coronary artery bypass grafting alternatives and other medical/surgical treatment options), with estimated current/forecast caseload across treatment types.

The report provides full year (actual) 2008 market size and share data, with forecast market data to 2017, for the U.S., Europe, Asia/Pacific and Rest of World.

The report details currently approved coronary stents, providing data on current and forecast impact on the market. The report also details the current state of product development in bare stents, drug-coated or drug-eluting stents and bioabsorbable stents in coronary applications and details the products under development, the anticipated timeline and impact of their market introduction. The report assesses the current and ten-year forecast global market for coronary stents, with segmentation by U.S., Europe, Asia/Pacific and Rest of World. The report provides competitor market shares by these geographic regions. The leading and key emerging coronary stent manufacturers are profiled with current product offerings, development status and market strengths/advantages.

Table of Contents:

EXECUTIVE SUMMARY

SECTION 1:   CLINICAL BACKGROUND

1.1       Cardiovascular Disorders Applicable for Stent Implantation
1.1.1    Acute Closure
1.1.2    Restenosis After Angioplasty
1.2       Risk Factors for Coronary Heart Disease
1.3       Stenting vs. CABG and Angioplasty
1.4       Alternative Therapies for Coronary Atherosclerosis
1.4.1    Angioplasty With or Without Stenting
1.4.2    Atherectomy
1.4.3    Coronary Artery Bypass Graft (CABG)
1.4.3.1 Open CABG
1.4.3.2 Off-Pump Coronary Artery Bypass (OPCAB)
1.4.3.3 MIDCAB (Minimally Invasive Direct Coronary Bypass)
1.4.3.4 RACAB (Robotic Assisted Coronary Artery Bypass)
1.4.3.5 Other Forms of CABG
1.4.4    Transmyocardial Laser Revascularization (TMR)
1.4.5    Genetic Therapies
1.4.6    HDL Therapy
1.4.7    Drug-Eluting Balloons
1.4.8    Nanoparticles and Other Agents
1.5       Incidence and Prevalence of Cardiovascular Stenting Procedures
1.6       Complications Related to Cardiovascular Stents

SECTION 2:   PRODUCTS, TECHNOLOGIES
2.1       Materials Used in Cardiovascular Stents
2.2       Various Stent Shapes and Resulting Impact
2.3       FDA Approval of Cardiovascular Stents
2.4       Reimbursement of Drug-Eluting Stents
2.5       Bare Metal Stents
2.6       Drug-Eluting Stents
2.6.1    Abbott Vascular
2.6.2    Boston Scientific
2.6.3    Johnson & Johnson/Cordis
2.6.4    Medtronic
2.6.5    Other Drug-Eluting Stent Companies
2.7       Bioabsorbable Stents
2.8       Other Types of Stents
2.9       Legal Proceedings
2.10     Key Clinical Trials
2.10.1  HORIZONS AMI
2.10.2  SYNTAX
2.10.3  SPIRIT
2.10.4  COURAGE
2.10.5  PROTECT
2.10.6  ENDEAVOR
2.10.7  FAME
2.10.8  SORT OUT III
2.10.9  DAPT
2.10.10  ZEST

SECTION 3:   MARKETS FORECASTS AND COMPETITOR SHARES
3.1       Worldwide Market for Coronary Stents
3.1.1    Worldwide Market for Drug-Eluting Coronary Stents
3.1.2    Worldwide Market for Bare Metal Coronary Stents
3.1.3    Worldwide Market for Absorbable Coronary Stents
3.2       U.S. Market for Coronary Stents
3.2.1    U.S. Market for Drug-Eluting Coronary Stents
3.2.2    U.S. Market for Bare Metal Coronary Stents
3.2.3    U.S. Market for Absorbable Coronary Stents
3.3       European Market for Coronary Stents
3.3.1    European Market for Drug-Eluting Coronary Stents
3.3.2    European Market for Bare Metal Coronary Stents
3.3.3    European Market for Absorbable Coronary Stents
3.4       Asia/Pacific Market for Coronary Stents
3.4.1    Asia/Pacific Market for Drug-Eluting Coronary Stents
3.4.2    Asia/Pacific Market for Bare Metal Coronary Stents
3.4.3    Asia/Pacific Market for Absorbable Coronary Stents
3.5       Rest of World (ROW) Market for Coronary Stents
3.5.1    ROW Market for Drug-Eluting Coronary Stents
3.5.2    ROW Market for Bare Metal Coronary Stents
3.5.3    ROW Market for Absorbable Coronary Stents

SECTION 4:   COMPANY PROFILES
4.1       Aachen Resonance GmbH
4.2       Abbott Vascular
4.3       AdvanSource Biomaterials Corporation
4.4       Aeon Bioscience
4.5       Allvivo Vascular, Inc.
4.6       Amaranth Medical, Inc.
4.7       amg International GmbH
4.8       Arterial Remodeling Technologies (ART)
4.9       Atrium Medical
4.10     Avantec Vascular
4.11     B. Braun Melsungen
4.12     Balton Ltd.
4.13     Bioabsorbable Therapeutics, Inc.
4.14     Bioring SA
4.15     Biosensors International
4.16     Biotronik
4.17     Blue Medical Devices B.V.
4.18     Boston Scientific
4.19     Caliber Therapeutics
4.20     Cappella Inc.
4.21     CardioMind, Inc.
4.22     CeloNova BioSciences, Inc.
4.23     CID S.r.l. (Formerly Sorin Vascular Therapy)
4.24     Cinvention AG (Formerly Blue Membranes)
4.25     CorNova
4.26     CV Therapeutics/Gilead Inc.
4.27     Devax
4.28     DISA Vascular
4.29     Elixir Medical Corp.
4.30     Estracure Inc.
4.31     eucatech AG
4.32     Genesis Technologies, LLC
4.33     Global Therapeutics (Cook Medical)
4.34     Hexacath
4.35     ICON Interventional (Formerly ICON Medical Corp.)
4.36     InspireMD
4.37     InTek Technology
4.38     Invatec s.r.l.
4.39     ITGI Medical Ltd.
4.40     Johnson & Johnson
4.40.1  Cordis
4.40.2  Conor Medsystems (J&J)
4.41     JW Medical Systems / Biosensors International
4.42     Kaneka Corporation
4.43     Kyoto Medical Planning Co., Ltd.
4.44     Lepu Medical
4.45     Lutonix, Inc.
4.46     Medinol/ARIAD Pharmaceuticals
4.47     Medlogics Device Corporation (MDC)
4.48     Medtronic Vascular
4.49     Miami Cardiovascular Innovations
4.50     Micell Technologies
4.51     MicroPort Scientific Corporation
4.52     Minvasys
4.53     MIV Therapeutics
4.54     mNEMOSCIENCE GmbH
4.55     MoBeta, Inc.
4.56     NanoInterventions, LLC
4.57     Neovasc, Inc.
4.58     Nexeon MedSystems, Inc.
4.59     Opto Circuits (India) Ltd.
4.59.1  EuroCor GmbH
4.60     OrbusNeich
4.61     Palmaz Scientific, Inc.
4.62     Picarus NV
4.63     Possis Medical (Bayer)
4.64     Prescient Medical
4.65     Relisys Medical Devices
4.66     REVA Medical
4.67     Sahajanand Medical Technologies
4.68     Stentys SAS
4.69     Terumo
4.70     Translumina
4.71     TriReme Medical
4.72     Tryton Medical
4.73     Vascular Concepts
4.74     VasoTech, Inc.
4.75     X-Cell Medical
4.76     Xtent, Inc. (August 3, 2009:  Xtent shareholders approve plan to dissolve and liquidate company after it is unable to raise the necessary funds to continue its stent development.)

APPENDIX I:  SELECTED CLINICAL TRIALS

ABSORB
ARRIVE II Registry
ARTS
AXXESS PLUS
BASKET
BBC ONE
CARE
COREL
COSTAR
COURAGE
CUSTOM
DEScover Registry
DIRECT
DIVERGE
e-HEALING
EASTER Registry
ENDEAVOR
ETHOS
EuroSTAR
EVENT Registry
FAME
GENESIS
FOCUS
HEALING
HORIZONS-AMI
ISAR, ISAR-TEST-2
LONG DES
NOBLESS
NOBORI
NORDIC
OLYMPIA Registry
PASSION
PREPARE
PROGRESS
RESOLUTE
RESORB
REWARD Registries
SERIES
SIMPLE Registries
SIRIUS, E-SIRIUS, C-SIRIUS
SORT-OUT III
SPIRIT
STEALTH
STEMI
STENT Registry
SVELT
TAXUS
TYPHOON
ZEST-AMI
ZOMAXX
APPENDIX II:  COMPANY DIRECTORY

List of Exhibits

Exhibit ES-1: Types of Cardiovascular Disease and Incidence in the United States, 2006
Exhibit ES-2: Prevalence, Mortality and Hospital Discharges for Cardiovascular Disease Patients in the United States
Exhibit ES-3: Potential Complications Related to Implantation of Cardiovascular Stents
Exhibit ES-4: Types of Coronary Stents and Selected Anti-Restenosis Devices
Exhibit ES-5: Worldwide DES Market by Company, Calendar 4th Quarter, 2008
Exhibit ES-6: Worldwide Market for Coronary Stents, by Type, Revenue Forecast, 2008–2017
Exhibit ES-7: Worldwide Market for Drug-Eluting Coronary Stents, by Region, Revenue Forecast, 2008–2017
Exhibit ES-8: Worldwide Market for Bare Metal Coronary Stents, by Region, Revenue Forecast, 2008–2017
Exhibit ES-9: Worldwide Market for Absorbable Coronary Stents, by Region, Revenue, 2012–2017

Exhibit 1-1: Types of Cardiovascular Disease and Incidence in the United States, 2006
Exhibit 1-2: International Death Rates Per 100,000 Population for Total Cardiovascular Disease and Coronary Heart Disease for the Top 20 Countries
Exhibit 1-3: Prevalence, Mortality and Hospital Discharges for Cardiovascular Disease Patients in the United States
Exhibit 1-4: Drug-Eluting Balloon Catheters
Exhibit 1-5: Estimated Inpatient Cardiovascular Procedures, U.S., 2006 (000)
Exhibit 1-6: Number of Discharges, Coronary Atherosclerosis, U.S.
Exhibit 1-7: National Healthcare Cost and Utilization Project Statistics: Mean Charges and In-Hospital Death Rates for Various Cardiovascular Procedures, U.S.
Exhibit 1-8: Total Number of Cardiac Revascularization Discharges and Mean Charges, U.S., 1993–2006
Exhibit 1-9: Total Number of Discharges for PCI Procedures with Non-Drug-Eluting Stents and Mean Charges, U.S., 2002–2006
Exhibit 1-10: Total Number of Discharges for PCI Procedures with Drug-Eluting Stents and Mean Charges, U.S., 2002–2006
Exhibit 1-11: Total Number of Discharges for PCI Procedures with Non-Drug and Drug-Eluting Stent Discharges and Mean Charges, U.S., 2002–2006

Exhibit 2-1: Competitors in the Market for Bare Metal Stents
Exhibit 2-2: Competitors in the Market for Drug-Eluting Stents
Exhibit 2-3: Competitors in the Market for Bioresorbable Stents
Exhibit 2-4: Competitors in the Market for Novel Stent Technologies

Exhibit 3-1: Worldwide Coronary Stent Market, Unit and Revenue Forecast, 2008-2017
Exhibit 3-2: Worldwide Drug-Eluting Coronary Stent Market, Unit and Revenue Forecast, 2008-2017
Exhibit 3-3: Revenues for Leading Drug-Eluting Stent Market Competitors, Worldwide, 2008
Exhibit 3-4: Worldwide Coronary Bare Metal Stent Market, Unit and Revenue Forecast, 2008-2017
Exhibit 3-5: Worldwide Coronary Absorbable Stent Market, Unit and Revenue Forecast, 2012-2017
Exhibit 3-6: U.S. Market for Coronary Stents, by Type, Revenue Forecast, 2008-2017
Exhibit 3-7: U.S. Coronary Drug-Eluting Stent Market, Unit and Revenue Forecast, 2008-2017
Exhibit 3-8: Revenues for Leading Drug-Eluting Stent Market Competitors, United States, 2008
Exhibit 3-9: U.S. Coronary Bare Metal Stent Market, Unit and Revenue Forecast, 2008-2017
Exhibit 3-10: U.S. Coronary Absorbable Stent Market, Unit and Revenue Forecast, 2013-2017
Exhibit 3-11: European Coronary Stent Market, by Type, Revenue Forecast, 2008-2017
Exhibit 3-12: European Drug-Eluting Stent Market, Unit and Revenue Forecast, 2008-2017
Exhibit 3-13: European Coronary Bare Metal Stent Market, Unit and Revenue Forecast, 2008-2017
Exhibit 3-14: European Coronary Absorbable Stent Market, Unit and Revenue Forecast, 2013-2017
Exhibit 3-15: Asia/Pacific Market Forecasts for Coronary Stents, by Type, Revenue Forecast, 2008-2017
Exhibit 3-16: Asia/Pacific Drug-Eluting Stent Market, Unit and Revenue Forecast, 2008-2017
Exhibit 3-17: Asia/Pacific Coronary Bare Metal Stent Market, Unit and Revenue Forecast, 2008-2017
Exhibit 3-18: Asia/Pacific Coronary Absorbable Stent Market, Unit and Revenue Forecast, 2012-2017
Exhibit 3-19: Rest of World Coronary Stent Market, by Type, Revenue Forecast 2008-2017
Exhibit 3-20: Rest of World Drug-Eluting Stent Market, Unit and Revenue Forecast, 2008-2017
Exhibit 3-21: Rest of World Coronary Bare Metal Stent Market, Unit and Revenue Forecast, 2008-2017
Exhibit 3-22: Rest of World Coronary Absorbable Stent Market, Unit and Revenue Forecast, 2012-2017

Exhibit 4-1: AdvanSource Biomaterials Third Quarter Financial Results ($000s)
Exhibit 4-2: Medtronic Financial Data, Third Quarter 2009 ($millions)
Exhibit 4-3: Medtronic’s Coronary Stent Revenues, FY 2008 & 2009 ($millions)
Exhibit 4-4: Xtent Financial Data, Fourth-Quarter 2008 ($millions)

For more please visit
http://www.bharatbook.com/Market-Research-Reports/Worldwide-Market-for-Drug-Eluting-Bare-and-Other-Coronary-Stents-2008-2017.html

Spine Surgery Worldwide 2008-2017: Products, Technologies, Markets and Opportunities

This report details the complete range of products and technologies in spine surgery, including the surgical management of spine disorders, diseases and trauma, with treatments including use of grafts, demineralized bone, fusion, stabilization, disc replacement, nucleus replacement, vertebroplasty, kyphoplasty, imaging, minimally invasive surgical technologies, energy-based therapies and biologics. The report details current clinical and technology developments in the huge and rapidly growing spine surgery technologies worldwide market, with data on products in development and on the market; market size and forecast; competitor market shares; competitor profiles; and market opportunity.

This report is a detailed market and technology assessment and forecast of the products and technologies in the management of diseases and disorders of the spine. The report describes diseases and disorders of the spine, encompassing congenital disorders, inflammatory and infectious diseases; degenerative diseases; herniations, stenoses, myelopathies and other “mechanical” disorders of the spine; spinal trauma; tumors of the spine; and others. The report characterizes the patient populations, their current clinical management, and trends in clinical management as new techniques and technologies are expected to be developed and emerge. The report details the currently available products and technologies, and manufacturer offerings. The report details products and technologies under development and markets for each in spine surgery. The report provides a current and forecast assessment of the worldwide markets for these technologies, with geographic segmentation by U.S. & Canada, European Union (detailing France, United Kingdom, Germany, Italy and Spain), Japan and Rest of World. The report provides emphasis on the market impact of new technologies through the coming decade, profiling nearly 100 active companies in this industry, with comprehensive detail on key companies, providing data on their current products, current market position and products under development.

Table of Contents:

Executive Summary
Non-fusion products
Disc arthroplasty (total disc replacement)
Nuclear arthroplasty
European Union
Asia-Pacific
Rest of World
Selected company-related events
Medtronic
LDR Spine
Synthes Spine
Disc Motion Technologies
Spine Structure
Products and technologies
CMS, carriers reverse decision on artificial discs
Cost effectiveness

For more please visit
http://www.bharatbook.com/Market-Research-Reports/Spine-Surgery-Worldwide-2008-2017-Products-Technologies-Markets-and-Opportunities.html

Ablation Technologies Worldwide Market, 2008-2017: Products, Technologies, Markets, Companies and Opportunities

This report is a detailed market and technology assessment and forecast of the products and technologies in the ablation market for treatment of soft tissues via energy-based modalities, including electrosurgery, radiosurgery, gamma knife, brachytherapy, cryogenic therapy, fluidjet therapy (hydrotherapy), microwave ablation, radiofrequency ablation, laser, thermal ablation, and ultrasonic ablation.

The report describes alternative energy-based technologies and the nature of their effect on soft tissue, the underlying basis of the technology, the requisite systems for their use (including capital equipment, devices and disposables), and their strengths and weaknesses for specific clinical applications. The report details current and anticipated target applications and assesses the current and forecast caseload for each energy-based therapeutic considering competition from any and all alternative energy-based or other therapeutics, with current and worldwide market forecasts (2008-2017) segmented by technology type and specific clinical segment. The report provides segmentation of the worldwide ablation market by both ablation technology and region/country: Americas (USA, Canada, Mexico, Brazil), Europe (Germany, United Kingdom, France, Italy, Spain, BeNeLux), Asia/Pacific (Japan, China, India, Australia) and Rest of World. The report details the current and emerging products, technologies and markets for each energy-based therapy. The report profiles over 60 key companies in this industry detailing their current products, current market position and products under development.

Table of Contents:

EXECUTIVE SUMMARY
Overview
Trends and Opportunities
Market Leaders

SECTION 1: ENERGY-BASED THERAPIES BY DISEASE STATE AND TECHNOLOGY
1.1 Cancer
1.1.1 Cryogenic therapy
1.1.2 Microwave therapy
1.1.3 Radiation therapy
1.1.4 Radiofrequency ablation
1.1.5 Stereotactic surgery
1.1.6 Thermal ablation
1.1.7 Laser ablation
1.1.8 Photodynamic therapy
1.1.9 Ultrasonic ablation
1.2 Cardiovascular disease
1.2.1 Angina pectoris
1.2.2 Atrial arrhythmias
1.2.2.1 Laser ablation
1.2.2.2 Cryoablation
1.2.2.3 Electrical cardioversion
1.2.2.4 Microwave ablation
1.2.2.5 RF ablation
1.2.3 Bradycardia
1.2.4 Critical ischaemia
1.2.5 Vascular occlusive disease
1.2.6 Ventricular arrhythmias
1.2.7 Wolf-Parkinson-White Disease
1.3 Elective surgery
1.3.1 Cosmetic surgery
1.3.1.1 Laser hair removal
1.3.1.2 Port wine stains
1.3.1.3 Psoriasis
1.3.1.4 Varicose veins
1.3.2 Ophthalmic surgery
1.3.2.1 Capsulotomy surgery
1.3.2.2 Laser in-situ keratomileusis (LASIK)
1.3.2.2.1 Wave-front guided laser in-situ keratomileusis
1.3.2.3 Laser epithelial keratomileusis (LASEK)
1.4 General surgery
1.4.1 Fecal incontinence
1.4.2 GERD
1.5 Gynecological applications
1.5.1 Hysterectomy
1.5.2 Menorrhagia
1.5.3 Bladder neck suspension
1.5.4 Fibroids
1.6 Urological applications
1.6.1 Urinary tract stones
1.6.2 Benign prostatic hypertrophy
1.6.2.1 TUMT
1.6.2.2 TUNA
1.6.2.3 Vaporization of the prostate (PVP)
1.6.2.4 Water-induced thermotherapy
1.7 Orthopedic applications
1.7.1 Capsular shrinkage
1.7.2 Carpal tunnel syndrome
1.7.3 Chondroplasty
1.7.4 Debridement
1.7.5 Epicondylitis and tendinitis
1.7.6 Inflammatory conditions
1.7.7 Nucleoplasty

Section 2: PRODUCTS AND TECHNOLOGIES
2.1 Cryogenic energy
2.2 Electrical energy
2.2.1 Implantable cardioverter defbibrillators
2.2.2 Resynchronisation systems
2.2.3 Pacing systems
2.2.4 Pain management
2.3 Hydromechanical energy
2.4 Light energy
2.4.1 Cold lasers
2.4.2 Excimer lasers
2.4.3 Photonic ablation
2.4.4 Ultraviolet B lasers
2.5 Microwave energy
2.6 Radiation energy
2.6.1 Brachytherapy
2.6.2 Radiosurgery
2.6.2.1 Cyberknife
2.6.2.2 Gamma knife
2.7 Radiofrequency energy
2.8 Thermal energy
2.9 Ultrasonic energy
2.9.2.1 Shock wave therapy
2.9.2.2 Ultrasonic surgical systems

Section 3: ABLATION TECHNOLOGIES MARKET
3.1 World market overview
3.2 Market segmentation by product type
3.3 Leading companies in global market
3.4 Major national markets
3.4.1 Americas
3.4.1.1 USA
3.4.1.2 Canada
3.4.1.3 Mexico
3.4.1.4 Brazil
3.4.2 Europe
3.4.2.1 Germany
3.4.2.2 United Kingdom
3.4.2.3 France
3.4.2.4 Italy
3.4.2.5 Spain
3.4.2.6 Benelux countries
3.4.3 Asia/Pacific
3.4.3.1 Japan
3.4.3.2 China
3.4.3.3 Australia
3.4.3.4 South Korea
3.4.3.5 India
3.4.4 Rest of world

Section 4: COMPANY PROFILES
4.1 The Industry
4.1.1 Abla-TX
4.1.1.1 Role in Cancer Treatment
4.1.2 Acoustic MedSystems
4.1.3 Accuray
4.1.4 ACMI/Gyrus/Olympus
4.1.5 AFx (Guidant)
4.1.6 Alcon
4.1.7 American Medical Systems
4.1.8 Angiodynamics
4.1.8.1 Financials
4.1.9 ArthroCare Corporation
4.1.10 AtriCure, Inc.
4.1.11 ATS Medical
4.1.11.1 Financial results
4.1.12 Bard EP
4.1.13 Bausch & Lomb (Warburg Pincus)
4.1.14 Baylis Medical Company
4.1.15 Biosense Webster
4.1.16 Biotronik Inc.
4.1.17 Biowave Corp
4.1.18 Boston Scientific Corp
4.1.18.1 Blazer Cardiac Ablation Catheters
4.1.18.2 Chilli Cooled Ablation Catheters
4.1.18.3 Steerocath-T Cardiac Ablation Catheter
4.1.18.4 Maestro
4.1.18.5 RF 3000® Radiofrequency Ablation System
4.1.18.6 Confient Implantable Cardioverter Defibrillator (ICD)
4.1.18.7 Financials
4.1.19 BSD Medical Corp.
4.1.19.1 MicroThermX-100 Microwave Ablation Systems
4.1.19.2 BSD500 Hyperthermia Systems
4.1.19.3 BSD2000 Hyperthermia Systems
4.1.20 Candela Corp.
4.1.21 Cardima Inc
4.1.22 CardioGenesis Corp
4.1.23 Celon AG
4.1.23.1 Surgery/Radiology
4.1.23.2 Phlebology
4.1.24 Celsion Corp.
4.1.25 ConMed Corp.
4.1.26 Covidien Ltd.
4.1.26.1 Vessel Sealing
4.1.26.2 Electrosurgery
4.1.26.3 Financial Results for fiscal 2007 and 2006
4.1.27 CryoCath
4.1.28 CryoCor, Inc.
4.1.29 CSA Medical Inc.
4.1.30 Cytyc Corp.
4.1.31 Dornier MedTech
4.1.31.1 Compact Delta II
4.1.31.2 Compact Delta II UIMS
4.1.31.3 Compact Sigma
4.1.31.4 Lithotripter S II
4.1.31.5 Medilas D MultiBeam
4.1.31.6 Medilas D FlexiPulse
4.1.31.7 Medilas H 20
4.1.32 EDAP TMS S.A.
4.1.32.1 Financial Update
4.1.33 Elekta
4.1.33.1 Leksell Gamma Knife 4
4.1.33.2 Leksell Gamma Knife 4C
4.1.33.3 Leksell Gamma Knife Perfexion
4.1.34 Endocare (merged with Galil Medical)
4.1.35 Erbe
4.1.35.1 Electrosurgery
4.1.35.2 Water Jet Surgery
4.1.35.3 Cryosurgery
4.1.36 Ethicon Endo-Surgery Inc.
4.1.37 Galil Medical (merged with Endocare)
4.1.38 Getinge Group
4.1.38.1 Cardiac Surgery
4.1.38.2 Vascular Surgery
4.1.39 HealthTronics Surgical Services
4.1.39.1 Medical Products
4.1.39.2 Urology Services
4.1.40 Medtronic
4.1.40.1 Cardiac Rhythm Disease Management (CRDM)
4.1.40.2 Bradycardia
4.1.40.3 Tachyarrhythmia
4.1.40.4 Ablation Catheters
4.1.41 MedWaves Inc.
4.1.42 Mirabilis Medica
4.1.43 Misonix Inc.
4.1.43.1 Sonablate
4.1.44 NeuWave Medical Inc.
4.1.45 Olympus Medical
4.1.46 OmniSonics Medical Technologies Inc. — filed for Chapter 7 bankruptcy in March 2009
4.1.47 PhotoMedex Inc.
4.1.48 PhotoTherapeutics Inc.
4.1.49 PhotoThera Inc.
4.1.50 RFA Medical Inc.
4.1.51 Smith & Nephew
4.1.51.1 Financial Results
4.1.52 Spectranetics
4.1.53 St Jude Medical Inc.
4.1.53.1 Products for Cardiac Rhythm Management
4.1.53.2 Atrial Fibrillation
4.1.53.3 Advanced Neuromodulation Systems
4.1.54 Starion Instruments
4.1.55 Stereotaxis Inc.
4.1.55.1 Stereotaxis Magnetic Navigation System
4.1.56 Theragenics Corporation
4.1.57 Urologix Inc
4.1.57.1 Targis System
4.1.58 USHIFU
4.1.59 Varian Medical Systems Inc.
4.1.59.1 RapidArc
4.1.59.2 Dynamic Targeting Image-Guided Radiation Therapy (IGRT)
4.1.59.3 SmartBeam IMRT
4.1.59.4 Dynamic Adaptive Radiotherapy (DART)
4.1.59.5 IGBT - Image-Guided Brachytherapy
4.1.59.6 Varian Proton Therapy System
4.1.60 VNUS Medical Technologies, Inc.
4.1.60.1 ClosureFAST System
4.1.60.2 Model RFG2 Advanced Radiofrequency Generator
4.1.60.3 Quarterly Financials
APPENDIX: COMPANY DETAILS

List of Exhibits

Exhibit ES-1: Overview of the Global Ablation and Other Energy-Based Therapies Market by Modality
Exhibit ES-2: Growth of the Worldwide Ablation and Other Energy-Based Therapies Market by Modality
Exhibit ES-3: Worldwide Ablation and Other Energy-Based Therapies Market by Clinical Application
Exhibit ES-4: Market Leaders in Energy-Based Therapies

Exhibit 1-1: Energy-Based Treatment Options for Prostate Cancer
Exhibit 1-2: Energy-Based Therapies for Cardiovascular Diseases
Exhibit 1-3: Energy-based Therapies for Atrial Arrhythmias
Exhibit 1-4: Ventricular Arrhythmia Therapies
Exhibit 1-5: Energy-based Implants for Ventricular Arrhythmias
Exhibit 1-6: Cosmetic Lasers
Exhibit 1-7: Traditional LAVH vs PK LVAH
Exhibit 1-8: Orthopedic Application of Electrosurgical Devices
Exhibit 1-9: Collagen Types
Exhibit 1-10: Chondroplasty Systems’ Zone of Thermal Damage

Exhibit 2-1: Energy-Based Technologies
Exhibit 2-2: Cryogenic-Energy Ablation Products
Exhibit 2-3: Electrical-Energy Ablation Products
Exhibit 2-4: Hydromechanical Ablation Products
Exhibit 2-5: Light-Energy Ablation Products
Exhibit 2-6: Microwave Ablation Products
Exhibit 2-7: Radiation-Energy Ablation Products
Exhibit 2-8: Radioactive Seed Products for Brachytherapy
Exhibit 2-9: Radiofrequency (RF) Ablation Products
Exhibit 2-10: Thermal-Energy Ablation Products
Exhibit 2-11: Ultrasound Ablation Products
Exhibit 2-12: High Growth Applications of Ultrasonic Surgical Systems

Exhibit 3-1: World Medical Device Market, by Region, 2008
Exhibit 3-2: World Energy-based Device Market by Product Category, 2007
Exhibit 3-3: Overview of the Energy-Based Therapies Market by Clinical Application
Exhibit 3-4: Arrhythmias Treated with Ablation Therapy
Exhibit 3-5: 25-Year Changes in National Mortality Rates Due to Ischaemic Heart Disease
Exhibit 3-6: Cardiac Angioplasty Procedures Per 100,000 Population, By Country in 2000
Exhibit 3-7: Cardiac Dysrhythmias and Related Conditions
Exhibit 3-8: Solid cancers: Ablation Market Potential
Exhibit 3-9: World Age-Standardize Cancer Incidence per 100, 000 Population (All Ages), by Cancer Type
Exhibit 3-10: Global Energy-based Therapies Market, by Product Category
Exhibit 3-11: World Energy-based Device Market by Product Category, 2007 and 2017
Exhibit 3-12: Ablation and Energy-based Therapeutic Companies by Product Area, Indication and Market Shares, Worldwide, 2008
Exhibit 3-13: Ablation Market Revenues ($millions), Americas, by Country, 2007-2017
Exhibit 3-14: Ablation Market Revenues ($000s) US, by Product Segment, 2007-2017
Exhibit 3-15: Ablation Market Revenues ($000s), Canada, by Product Segment, 2007-2017
Exhibit 3-16: Ablation Market Revenues ($000s), Brazil, by Product Segment, 2007-2017
Exhibit 3-17: Ablation Market Revenues ($000s), Mexico, by Product Segment, 2007-2017
Exhibit 3-18: Ablation Market Revenues ($millions), Europe, by Country, 2007-2017
Exhibit 3-19: Ablation Market Revenues ($000s), Germany, by Product Segment, 2007-2017
Exhibit 3-20: Ablation Market Revenues ($000s), United Kingdom, by Product Segment, 2007-2017
Exhibit 3-21: Ablation Market Revenues ($000s), France, by Product Segment, 2007-2017
Exhibit 3-22: Ablation Market Revenues ($000s), Italy, by Product Segment, 2007-2017
Exhibit 3-23: Ablation Market Revenues ($000s), Spain, by Product Segment, 2007-2017
Exhibit 3-24: Ablation Market Revenues ($000s), BeNeLux, by Product Segment, 2007-2017
Exhibit 3-25: Ablation Market Revenues ($millions), Asia/Pacific, by Country, 2007-2017
Exhibit 3-26: Ablation Market Revenues ($000s), Japan, by Product Segment, 2007-2017
Exhibit 3-27: Ablation Market Revenues ($000s), China, by Product Segment, 2007-2017
Exhibit 3-28: Ablation Market Revenues ($000s), India, by Product Segment, 2007-2017
Exhibit 3-29: Ablation Market Revenues ($000s), Australia, by Product Segment, 2007-2017
Exhibit 3-30: Ablation Market Revenues ($millions), Rest of World, 2007-2017
Exhibit 3-31: Ablation Market Revenues ($000s), Rest of World, by Product Segment, 2007-2017

Exhibit 4-1: M&A Activity Among Energy-based Companies
Exhibit 4-2: AngioDynamics Financial Figures for Fiscal 2007 and 2006
Exhibit 4-3: ATS Financial Results for Q2 2008 and 2007
Exhibit 4-4: Boston Scientific Financials, Three Months Ended June 30, 2007 & 2008
Exhibit 4-5: CardioGenesis Financial Data, 2006 &2007
Exhibit 4-6: Covidien Ltd Financial Results, 2006 & 2007
Exhibit 4-7: Covidien Medical Device sales by Product Group
Exhibit 4-8: EDAP TMS Financial Results, 1st Quarter 2008 (to March 31st)
Exhibit 4-9: Endocare Quarterly Results, 2007 & 2008
Exhibit 4-10: Medtronic Revenues, 2007
Exhibit 4-11: Six-month Financial Data for Smith & Nephew, 2007 & 2008
Exhibit 4-12: TheraGenics Financial Results, Fourth Quarter 2007 and Full Year
Exhibit 4-13: Varian Medical Systems, Financial Summary, 2005-2007

For more please visit
http://www.bharatbook.com/Market-Research-Reports/Ablation-Technologies-Worldwide-Market-2008-2017-Products-Technologies-Markets-Companies-and-Opportunities.html

This report details the complete range of sealants & glues technologies used in traumatic, surgical and other wound closure, from tapes, sutures and staples to hemostats, fibrin sealants/glues and medical adhesives. The report details current clinical and technology developments in this huge and rapidly growing worldwide market, with data on products in development and on the market; market size and forecast; competitor market shares; competitor profiles; and market opportunity.

This report is a market and technology assessment and forecast of surgical sealants, glues, hemostasis, other wound closure and anti-adhesion. The report details the current and emerging products, technologies and markets involved in wound closure and sealing using sutures and staples, tapes, hemostats, fibrin and sealant products, medical adhesives and products to prevent surgical adhesions. The report provides a worldwide current and annual forecast to 2013 of the markets for these technologies, with particular emphasis on the market impact of new technologies through the coming decade. The report provides specific forecasts and shares of the worldwide market by segment for the U.S., Europe (United Kingdom, German, France, Italy, BeNeLux), Latin America, Japan and Rest of World.

The report provides background data on the surgical, disease and traumatic wound patient populations targeted by current technologies and those under development, and the current clinical practices in the management of these patients, including the dynamics among the various clinical specialties or subspecialties vying for patient population and facilitating or limiting the growth of technologies.

The report establishes the current worldwide market size for major technology segments as a baseline for and projecting growth in the market over a ten-year forecast. The report also assesses and projects the composition of the market as technologies gain or lose relative market performance over this period.

Table of Contents:

Executive Summary
Introduction
Demographic trends
Consumer-Driven Product Selection
Mechanisms of Tissue Repair
Commercial Imperatives
Industry Consolidation
Clinical Caseload
Market Segmentation and Dynamics
New Surgical Techniques Drive Market Opportunity
The Uses of Adjunctive Surgical Closure and Securement Products
Product Development History
Evolution of Commercial Markets for Sealants and Adhesives
Company Strategies — Overview

Section 1:          CLINICAL NEED, CASELOAD, AND PROCEDURE VOLUME
1.1         Anatomy and Physiology of Tissue Repair
1.2         The Skin
1.3         Internal Tissues and Organs
1.4         Wound Classification and Types
1.4.1         Classification by Morphology and Severity
1.4.2         Wound Classification by Cause
1.4.3         Surgical Wounds
1.5         Caseload
1.5.1         Cardiovascular
1.5.1.1         Coronary Heart Disease
1.5.1.2         Dysfunctional Heart Valves
1.5.1.3         Peripheral Vascular Disorders
1.5.1.4         Abnormal Aortic Aneurysms
1.5.1.5         Drivers of Caseloads for Cardiac Surgery
1.5.2         Neurological
1.5.2.1         Stroke
1.5.2.2         Parkinson’s Disease
1.5.2.3         Epilepsy
1.5.2.4         Traumatic Injury
1.5.2.5         Peripheral Nerve Treatment
1.5.2.6         Neurology Drivers
1.5.3         Orthopedic
1.5.3.1         Hip Replacements
1.5.3.2         Knee Replacements
1.5.3.3         Cartilage Repair
1.5.3.4         Ligament Damage
1.5.3.5         Bone Grafting
1.5.3.6         Vertebral Disc Repair
1.5.3.7         Drivers of Orthopedic Surgery
1.5.4         Urological
1.5.4.1         Incontinence
1.5.4.2         Drivers of Urological Surgery
1.5.5         Skin
1.5.5.1         Burns
1.5.5.2         Pressure Ulcers
1.5.5.3         Diabetic Ulcers
1.5.5.4         Venous Ulcers
1.5.5.5         Plastic Surgery
1.6         The Role of Modern Sealant, Securement and Hemostatic Products in Surgery
1.6.1         Fibrin Sealants
1.6.2         High-Strength Glues

Section 2:          SCIENCE, TECHNOLOGY, DEVELOPMENT, CLINICAL AND REGULATORY CHALLENGES
2.1         Tissue Healing
2.1.1         Hemostasis
2.1.2         Proliferation and Maturation
2.1.3         Factors That Affect Healing
2.2         Product Development
2.3         Development Timelines
2.3.1         Collagen and Thrombin Combination
2.3.2         Polyethylene Glycol Polymer (PEG)
2.3.3         Albumin Cross-Linked with Glutaraldehyde
2.3.4         Delivery Systems
2.4         Cost Effectiveness
2.5         Regulatory Challenges
2.5.1         Approval Processes
2.5.2         History of Product Development
2.5.3         Regulatory Aspects

Section 3:          PRODUCTS, TECHNOLOGIES, AND FORECAST OPPORTUNITY
3.1         Overview
3.2         Development Timeline
3.3         Sutures, Staples, and Other Mechanical Closure Devices
3.3.1         Competitors and Products
3.3.2         Suppliers
3.3.3         Product Development
3.3.4         Market Analysis and Forecast
3.4         Tapes
3.4.1         Competitors and Products
3.4.2         Products in Development
3.4.3         Market Analysis and Forecast
3.5         Hemostats
3.5.1         Competitors and Products
3.5.2         Products in Development
3.5.3         Market Analysis and Forecasts
3.6         Fibrin and Other Sealant Products
3.6.1         Competitors and Products
3.6.2         Products in Development
3.6.3         Fibrin and Sealant Market and Competitive Activity
3.7         High-Strength Medical Adhesives
3.7.1         Competitors and Products
3.7.2         Products in Development
3.7.3         Market Analysis and Forecasts
3.8         Post-Surgical Adhesion Prevention
3.8.1         Competitors and Products
3.8.2         Products in Development
3.8.3         Market Analysis and Forecasts
3.9         Wound Closure and Securement Markets: Global and Regional Analysis
3.9.1         Americas
3.9.1.1         United States
3.9.1.2         Latin America
3.9.2         Japan
3.9.3         Europe
3.9.4         Rest of World
3.10       Worldwide Markets By Country and Segment

Section 4:          Company Profiles
4.1 3DM, Inc. (3D-Matrix, Ltd.)
4.2 3M
4.3 Abbott Vascular
4.4 AccessClosure, Inc.
4.5 Adhezion Biomedical, LLC
4.6 Advanced Medical Solutions plc
4.7 Allerderm
4.8 Angiotech Pharmaceuticals, Inc.
4.9 Anika Therapeutics, Inc.
4.10 ARC Pharmaceuticals
4.11 Arch Therapeutics, Inc.
4.12 ArthroCare Corporation
4.13 Aso LLC
4.14 Aspen Surgical Products
4.15 Atrax Medical Group
4.16 Avery Dennison
4.17 B. Braun Melsungen AG
4.18 Bastos Viegas, s.a.
4.19 Baxter International Inc.
4.20 Bayer HealthCare
4.21 BD (Becton, Dickinson and Company)
4.22 Berlin Heart GmbH
4.23 Bernsco Surgical Supply
4.24 Biocoral Inc.
4.25 BioCore Medical Technologies, Inc.
4.26 Biogentis, Inc.
4.27 Biomet Inc.
4.28 BIOSTER a.s.
4.29 BioSyntech Canada Inc.
4.30 BSN Medical
4.31 C.R. Bard
4.32 Cardiovascular Sciences, Inc.
4.33 Carl Auffarth GmbH & Co. KG
4.34 Cardiva Medical, Inc.
4.35 Ceremed, Inc.
4.36 Chemence Ltd.
4.37 Chemopharma, s.a.
4.38 Cohera Medical, Inc.
4.39 Collagen Matrix, Inc.
4.40 Coloplast A/S
4.41 ConvaTec
4.42 Covidien Ltd.
4.43 CryoLife Inc.
4.44 CSIRO PhotoMedical Technologies
4.45 CSL Behring
4.46 CSMG Technologies, Inc.
4.47 CuraMedical BV
4.48 Cypress Medical Products
4.49 Derma Sciences, Inc.
4.50 Distrex Ibérica S.A.
4.51 DuPont Applied BioSciences
4.52 Entegrion, Inc.
4.53 FibroGen, Inc.
4.54 Fidia Advanced Biopolymers
4.55 Flamel Technologies SA
4.56 Forticell Bioscience
4.57 FzioMed Inc.
4.58 Gelita Medical BV
4.59 GEM srl
4.60 Genzyme Biosurgery Inc.
4.61 GluStitch, Inc.
4.62 Graceduty Company Limited
4.63 GramsMed, LLC
4.64 Haemacure Corporation
4.65 HAPTO Biotech Israel Ltd.
4.66 Hartmann Group
4.67 Harvest Technologies Corporation
4.68 HemCon Medical Technologies, Inc.
4.69 Hemostasis, LLC
4.70 HyperBranch Medical Technology, Inc.
4.71 Incisive Surgical, Inc.
4.72 Innovasa Corporation
4.73 Integra Lifesciences Corporation
4.74 I-Therapeutix, Inc.
4.75 Johnson & Johnson
4.76 Kaketsuken (Chemo-Sero-Therapeutic Research Institute)
4.77 Kensey Nash Corporation
4.78 Kimberly-Clark Health Care
4.79 Kinetic Concepts, Inc.
4.80 King Pharmaceuticals, Inc.
4.81 Kookbo Chemicals Co., Ltd. (KB Chem.)
4.82 Laboratoires Urgo (Urgo Medical)
4.83 Lewis Medical Supplies
4.84 LifeBond Ltd.
4.85 Lifecore Biomedical, Inc.
4.86 Lohmann & Rauscher
4.87 Marine Polymer Technologies
4.88 Medafor, Inc.
4.89 Medi Surgichem Pvt. Ltd.
4.90 MedTrade Products, Ltd.
4.91 Meyer-Haake GmbH Medical Innovations
4.92 Mölnlycke Health Care AB
4.93 Morris Innovative
4.94 Motex Healthcare Corp.
4.95 Myco Medical
4.96 NeatStitch Ltd.
4.97 Neose Technologies Inc. (Novo Nordisk)
4.98 Nycomed
4.99 Omrix Biopharmaceuticals Inc.
4.100 Pac-Kit Safety Equipment
4.101 Pfizer Inc.
4.102 Pharming Group NV
4.103 Plasma Technologies, Inc.
4.104 PlasmaSeal
4.105 Pluromed, Inc.
4.106 Polyganics
4.107 Polyheal Ltd.
4.108 ProFibrix BV
4.109 Progressive Surgical, Ltd.
4.110 Protein Polymer Technologies, Inc.
4.111 Radi Medical Systems AB
4.112 Resorba Wundversorgung GmbH & Co. KG
4.113 Scapa Group plc
4.114 Scion Cardio-Vascular, Inc.
4.115 Sea Run Holdings
4.116 Seton
4.117 Smith & Nephew plc
4.118 Starch Medical, Inc.
4.119 Stereoplast Ltd.
4.120 Sutura, Inc.
4.121 Synovis Life Technologies
4.122 SyntheMed, Inc.
4.123 Teleflex Medical
4.124 ThermoGenesis Corporation
4.125 Therus Corporation
4.126 Thrombotargets Corp.
4.127 Tissuemed Ltd.
4.128 TraumaCure, Inc.
4.129 TyRx Pharma Inc.
4.130 Vascular Solutions, Inc.
4.131 Vectura Group plc
4.132 Vivostat A/S
4.133 Z-Medica Corporation
4.134 Zimmer
4.135 ZymoGenetics, Inc.
APPENDIX: LIST OF COMPANIES

List of Exhibits
Exhibit ES-1: Recent Acquisitions in the Securement Segment
Exhibit ES-2: Introducers of New Securement Technologies to the U.S. Market
Exhibit ES-3: Definition of Surgical Closure and Securement Products
Exhibit ES-4: Incidence of Two Example Surgical Procedures with High Requirement for Adjunctive Products for Surgical Closure and Securement
Exhibit ES-5: U.S. FDA Approved Uses of Sealants, Glues, and Hemostats
Exhibit ES-6: Synthetic and Biological Sealant Competitors (Non-Fibrin Sealants)
Exhibit ES-7: Selected High-Strength Adhesive Companies and Their Strategies
Exhibit ES-8: Selected Sealant Product Companies and Their Strategies
Exhibit ES-9: Worldwide Growth in the Securement and Closure Market, 2006–2013

Exhibit 1-1: Skin Structure Illustrating Major Organelles and Skin Layers
Exhibit 1-2: Classification of Wounds by Morphology
Exhibit 1-3: Severity Classification of Wounds
Exhibit 1-4: Wound Classification by Etiology
Exhibit 1-5: Prevalence of Different Wound Types, 2008
Exhibit 1-6: Criteria for Adjunctive Use of Hemostats, Sealants, Glues and Adhesion Prevention Products in Surgery
Exhibit 1-7: Surgical Procedures with Potential for the Use of Hemostats, Sealants, Glues and Adhesion Prevention Products, Worldwide
Exhibit 1-8: Potential for Cardiovascular Applications, Prevalence of Applicable Surgical Applications
Exhibit 1-9: Potential for Neurological Applications, Prevalence of Applicable Disorders
Exhibit 1-10: Potential for Orthopedic Applications, Frequency of Major Surgical Interventions
Exhibit 1-11: Potential for Urological Applications, Prevalence of Applicable Disorders
Exhibit 1-12: Potential for Dermal Repair, Prevalence of Applicable Disorders
Exhibit 1-13: Applications of Fibrin and Other Sealants
Exhibit 1-14: Surgical Procedures Using Fibrin and Other Sealant Products (2009–2013)
Exhibit 1-15: Surgical Indications for High-Strength Glues (Europe, 2008)

Exhibit 2-1:  Factors That Affect Wound Healing
Exhibit 2-2: Timescales for Development of Closure and Sealant Products
Exhibit 2-3:  Variables Associated With Clinical Evaluation of Closure and Securement and Related Products

Exhibit 3-1: Manufacturers of Surgical Sutures, Staples, Clips, and Other Mechanical Closure Devices
Exhibit 3-2: Worldwide Sutures and Staples Market Forecast, 2009–2013
Exhibit 3-3: Worldwide Suture and Staples Market 2007, Share by Supplier
Exhibit 3-4: Companies Commercializing First Aid Technologies Often Used as Tapes for Closure
Exhibit 3-5: Worldwide Tapes Market Forecast, 2009-2013
Exhibit 3-6: Worldwide Tapes for Closure Market Share, 2007, by Supplier
Exhibit 3-7: Companies Commercializing Technologies in the Hemostat Category
Exhibit 3-8: Worldwide Hemostats Market Forecast, 2009–2013
Exhibit 3-9: Worldwide Hemostats Market Share, 2007, by Supplier
Exhibit 3-10: Companies Commercializing Technologies in the Sealants Category
Exhibit 3-11: Worldwide Sealants Market Forecast, 2009-2013
Exhibit 3-12: Worldwide Sealants Market Share, 2007, by Supplier
Exhibit 3-13: Companies Commercializing Cyanoacrylate-based High-Strength Medical Adhesives
Exhibit 3-14: Worldwide High-Strength Glues Market Forecast, 2009–2013
Exhibit 3-15: Worldwide High-Strength Glues Market Share 2007, by Supplier
Exhibit 3-16: Companies Commercializing Technologies in the Post-Surgical Adhesion Prevention Category
Exhibit 3-17: Worldwide Post-Operative Adhesion Prevention Market Forecast, 2009–2013
Exhibit 3-18: Worldwide Post Operative Adhesion Prevention Market Share, 2007, by Supplier
Exhibit 3-19:  Size and Growth of Wound Closure and Securement Market, World and Selected Countries, 2007
Exhibit 3-20: Wound Closure Market 2007, by Product Segments: The Major American Countries
Exhibit 3-21: Wound Closure Market 2007, by Product Segments: Japan
Exhibit 3-22: Wound Closure Market 2007, by Product Segments: Major European Countries
Exhibit 3-23: Wound Closure Market 2007, by Product Segments: Rest of World
Exhibit 3-24: Growth Forecast for Closure and Securement Market, 2009–2013

Exhibit 4-1: 3M, Selected Financial Data for 2007
Exhibit 4-2: Abbott Laboratories, Selected Financial Data for the First Nine Months of 2008
Exhibit 4-3: Advanced Medical Solutions’ Selected Financial Data for 2006 and 2007
Exhibit 4-4: Angiotech Pharmaceuticals’ Statement of Income for 2nd Quarter, 2008 (Ending June 30)
Exhibit 4-5: Anika Therapeutics’ Financial Results for 2006 and 2007
Exhibit 4-6: ArthroCare Corporation Financial Data
Exhibit 4-7: B. Braun Financial Data
Exhibit 4-8: Baxter International Financial Data
Exhibit 4-9: C.R. Bard, Inc. Financial Data for Nine Months Ending Sept. 30
Exhibit 4-10: Cardiovascular Sciences, Inc. Financial Data
Exhibit 4-11: Covidien, Selected Financial Data, 2007
Exhibit 4-12: CryoLife Financial Results, 2006 and 2007
Exhibit 4-13: Haemacure Corporation, Selected Financial Data
Exhibit 4-14: Integra Lifesciences, Financial Data
Exhibit 4-15: Johnson & Johnson Key Financial Data, 2006 and 2007
Exhibit 4-16: Kimberly-Clark Health Care Financial Data
Exhibit 4-17: King Pharmaceuticals Financial Data
Exhibit 4-18: Overview of Omrix’ Biosurgical Product Pipeline
Exhibit 4-19: Omrix Biopharmaceuticals Financial Data
Exhibit 4-20: Pfizer Financial Data for 2007 and 2006
Exhibit 4-21: Pharming Financial Data
Exhibit 4-22: Teleflex Inc. Financial Data
Exhibit 4-23: Vascular Solutions Financial Results
Exhibit 4-24: ZymoGenetics Financial Data, 3rd Quarter, 2008

For more please visit
http://www.bharatbook.com/Market-Research-Reports/Worldwide-Surgical-Sealants-Glues-Wound-Closure-and-Anti-Adhesion-Markets-2009-2013.html

Drug Delivery Markets: Implantable Injectable and Needle-Free Delivery Systems

With pharmaceutical companies increasingly looking for ways to extend the revenue-earning lifetime of their biggest products, drug delivery has become an important focus of the industry. Kalorama’s Drug Delivery Markets: Implantable / Injectable and Needle-Free Delivery Systems provides detail for business planners on the market for implantable / injectable delivery system markets.

Biopharmaceutical products are driving growth of needle-free systems; there will likely be significant increases in revenues in the vaccine arena. This report looks at that trend and reports current and forecasted revenues for the implantable/injectable drug delivery market, segmented into two main categories:

Needle-free drug delivery
Other Injectable/Implantable

Kalorama’s unique analysis offers segmentation of this market for:

Drug Delivery Techology Revenues
Pharmaceuticals Sold via Delivery Technology

This breakout makes the report relevant to business plans of either device technology companies or pharmaceutical concerns. (This market analysis does not include drug-eluding stents or prefilled or regular syringes. Kalorama considers these seperate markets)

With pharmaceutical companies increasingly turning to drug delivery to extend the revenue-earning lifetime of their biggest products, drug delivery has become an important focus of the pharmaceutical industry.

Kalorama’s Drug Delivery Markets: Implantable / Injectable and Needle-Free Delivery Systems, the second volume of Kalorama’s popular series focusing on global drug delivery systems markets, provides the definitive break down of the market for implantable / injectable delivery system markets. The report covers both pharmaceuticals sold through implantable/injectable delivery systems and the technologies themselves including:

This focused report provides information on the revenues for relevant companies and provides information critical to assessing the opportunities available in this market, including:

Detailed Profiles of Key Companies in Implantable/Injectable Delivery and Brief Round-Up of smaller players
Current Market Size and Forecasts to 2013
Needle-Free Cost Savings, Protein-Coated Microcrystal Technology, Nanotechnology, and Other Trends and Developments
New Products in Development

Kalorama’s trusted information-gathering process provides most accurate study of the implantable/injectable delivery drug market available today. Information and analysis presented in this report is based on extensive interviews with senior management of top companies in the industry. While major research literature and government information is culled, information is corroborated and key market insights originate from interviews with industry leaders.

Companies Profiled in the report include:

Alkermes, Inc.
ALZA Corp.
Antares Pharma, Inc.
Bioject Medical Technologies, Inc.
CyDex, Inc.
MGI Pharma, Inc
Nektar Therapeutics
Pacira Pharmaceuticals, Inc.
pSivida
SurModics, Inc
Zogenix Corporation
AP Pharma
Baxter BioPharma Solutions
QLT USA, Inc
Ypsomed Holding AG

Kalorama has also published Drug Delivery Markets: Oral Delivery, which details markets for oral technology enhancements which have increased drug product sales and extended patent life.

Table of Contents:
CHAPTER ONE: EXECUTIVE SUMMARY
Market Drivers
Market Size and Growth
Total Implantable/Injectable Drug Delivery Marke
The Implantable/Injectable Drug Delivery Only Market
Competitor and Market Analysis

CHAPTER TWO: INTRODUCTION
Scope and Methodology
Reasons for Injectable/Implantable Drug Delivery Systems
History of Injectable/Implantable Drug Delivery
Phases of Drug Action
Needle-Free Drug Delivery
Auto-injectors
Pen Injectors
Major Applications
Safety Concerns
Products
Implantable Drug Delivery
Mechanisms
Applications
Products
Sustained-Release Drug Delivery
Products
Targeted Injection Drug Delivery
Products
Lipsome
Niosome
Microspheres and Nanoparticles
Cyclodetrins
Prodrug
Polymeric Micelles
PEGylation

CHAPTER THREE: TRENDS AND DEVELOPMENTS
Drivers of the Implantable/Injectable Drug Delivery Market

Biologics
Cancer

Pen Injectors
Proprietary Product Development
Delivery Systems Placement Trends
Therapeutic Trends
Incorporation of Technology
Nanotechnology
Drug Delivery Development

Microsphere Technology
Targeted Technology
MicroChip Technology
Protein-Coated Microcrystal Technology
Needle-Free Delivery Development
Selected Products in Development

CHAPTER FOUR: MARKET SIZE AND GROWTH
The Total Implantable/Injectable Drug Delivery Market
Injectable/Implantable Delivery Technology Only Market
CHAPTER FIVE: COMPETITIVE AND MARKET ANALYSIS
Competitive Landscape
Market Analysis

CHAPTER SIX: COMPANY PROFILES
Alkermes, Inc.
ALZA Corp.
Antares Pharma, Inc.
Bioject Medical Technologies, Inc.
CyDex, Inc.
MGI Pharma, Inc
Nektar Therapeutics
Pacira Pharmaceuticals, Inc.
pSivida
SurModics, Inc
Zogenix Corporation

COMPANIES IN BRIEF
AP Pharma
Baxter BioPharma Solutions
QLT USA, Inc
Ypsomed Holding AG

APPENDIX: COMPANY DIRECTORY

TABLE OF EXHIBITS

CHAPTER ONE: EXECUTIVE SUMMARY
Figure 1-1 The Worldwide Market for Implantable/Injectable Drug Delivery Technology and Pharmaceuticals 2003-201

CHAPTER TWO: INTRODUCTION
Table 2-1 Sequence of Drug Action
Table 2-2 Marketed Products Using Liposomal Drug Delivery
Table 2-3 Marketed Products Using Nanoparticle Drug Delivery

CHAPTER THREE: TRENDS AND DEVELOPMENTS
Table 3-1 Select Products in Development by Drug Delivery Companies

CHAPTER FOUR: MARKET SIZE AND GROWTH
Table 4-1 The Worldwide Market for Implantable/Injectable Drug Delivery Technology and Pharmaceuticals 2003-2013
Figure 4-1 The Worldwide Market for Implantable/Injectable Drug Delivery Technology and Pharmaceuticals 2003-2013
Table 4-2 The Worldwide Market for Pharmaceuticals Utilizing Injectable/Implantable Drug Delivery by Type 2003-2013
Figure 4-2 The Worldwide Market for Pharmaceuticals Utilizing Injectable/Implantable Drug Delivery by Type 2003-2013
Table 4-3 The Worldwide Market for Pharmaceuticals Utilizing Injectable/Implantable Drug Delivery Market Share by Type 2003-2013
Figure 4-3 The Worldwide Market for Pharmaceuticals Utilizing Injectable/Implantable Drug Delivery Market Share by Type 2008
Figure 4-4 The Worldwide Market for Pharmaceuticals Utilizing Injectable/Implantable Drug Delivery Market Share by Type 2013
Table 4-4 The Worldwide Market for Injectable/Implantable Drug Delivery Systems by Pharmaceutical and Drug Delivery Component 2003-2013
Table 4-5 The Worldwide Market for Injectable/Implantable Drug Delivery Systems Distribution of Revenue by Pharmaceutical and Drug Delivery Component 2003-2013
Figure 4-5 The Worldwide Market for Injectable/Implantable Drug Delivery Systems Distribution of Revenue by Pharmaceutical and Drug Delivery Component 2008
Figure 4-6 The Worldwide Market for Injectable/Implantable Drug Delivery Systems Distribution of Revenue by Pharmaceutical and Drug Delivery Component 2013

CHAPTER FIVE: COMPETITIVE AND MARKET ANALYSIS
Table 5-1 Leading Suppliers of Implantable/Injectable Drug Delivery Technology
Figure 5-1 Cost per Million Injections by Injector Type

For more information kindly visit
http://www.bharatbook.com/Market-Research-Reports/Drug-Delivery-Markets-Implantable-Injectable-and-Needle-Free-Delivery-Systems.html

Medical answering service : Evolving Medical Information Call Centers through Performance Measurement and Process Improvement

Evolving Medical Information Call Centers through Performance Measurement and Process Improvement (PH124)

Reinvent Your Medical Information Call Centers:

Are your call loads decreasing because customers seek information via new avenues?
Do you face info-sharing competition within your own organization?
What new areas demand medical information expertise?

Evolving Medical Information Call Centers addresses these questions — and more — to give your company the boost needed to

correct your call centers’ mistakes and evolve the group into new territories. Our study contains real-world data and best practices

from top pharmaceutical companies’ medical information call center operations.

With customers able to find product information on the Internet or from other sources — and with internal teams encroaching on

territory previously owned by medical information groups — call center leaders now face a number of potentially function-changing

challenges.

Top teams combat the evolving landscape by tightening their own ships – which means enacting performance metrics and process

improvements to become more efficient and to strengthen customer relationships. Additionally, medical information call centers

continue to move into new areas, adding tasks where their skill sets translate well.

This research developed to help medical information call center leaders in their improvement efforts. The report makes its case in

three easy-to-navigate chapters:

Medical Information Structures, Headcounts and Budgets – As the first major point of contact between patients and doctors and the

company, call centers set the tone between customers and the firm. For medical information teams to deliver the highest quality

service, they must be structured well and own sufficient headcounts and budgets. This chapter investigates structure and staffing

choices while determining how these influence call center budgets.

Call Center Performance Measurement – Surprisingly, metrics tracking is a largely under-utilized practice in medical information call

centers. In this threatening environment, however, the first step toward improvement is tracking and measuring call center metrics.

This chapter examines what measures companies currently track — and which ones all centers should be tracking. Benchmarks help

call centers compare themselves against centers at top pharma companies.

Call Center Process Improvement – Pharmaceutical companies that focus on making their call centers efficient, available and easy to

navigate will earn customer raves. To ensure that customers have good experiences, medical information leaders build sound

processes into their call centers. This chapter provides details of call center processes such as answering systems, agent availability,

triage systems as well as response methodologies and internal communication.

Table of Contents:

Chapter 1: Medical Information Structures, Headcounts and Budgets

* Percentage of companies with centralized structure
* Ratio of internal vs. outsourced call centers
* Percentage of outsourced call center operations in US vs ex-US
* Call center staffing
* Levels of education represented in call centers
* Mix of education levels represented in call centers
* Medical information budgets
* Source of medical information budgets
* Percentage of budget allocated to salaries
* Brand-level medical information spending

Chapter 2: Call Center Performance Measurement: Tracking Key
Metrics

* Call center metrics tracked
* Average total number of inbound and outbound calls per center
* Average total number of calls per FTE (monthly and annually)
* Ratio of inbound vs. outbound calls
* Expected vs. actual turn-around time
* Percentage actual turn-around time exceeds expected
* Average on-hold times
* Average abandonment rates
* Customer satisfaction rating
* Cost per call
* Number of written responses disseminated annually

Chapter 3: Call Center Process Improvement

* Sources of medical information inquiries
* Percentages of companies with IVR systems in place
* Days and hours individual call centers are open each week
* Percentage of companies with medical information personnel available during business hours
* Utilization of external medical experts
* After-hours availability of medical information specialists
* Ratio of written to verbal responses
* Percentage of companies with specific types of written documents available
* Ratio of response delivery (fax, e-mail, mail)
* Percentage of departments offering written material on investigational products
* Percentage of companies with websites for FAQs and/or standard letters
* Stakeholder feedback mechanisms

Sample Content from the Report

Excerpted from Chapter 2 of “Evolving Medical Information Call Centers.” The full report contains a number of real companies’

performance measures.

Customer Satisfaction/Call Quality
Somewhat shockingly, customer satisfaction is only measured by 40% of companies surveyed. While medical information call

centers do not sell, customer satisfaction is still something that all should track. Measuring satisfaction informs call center leaders on

whether their teams are relaying information clearly and concisely. While reps are not selling and trying to earn clients back, this is

another opportunity for pharma companies to “touch” their prescribers and patients.

Figure 2.16 [data figure appears in full report] shows the two companies reporting their customer satisfaction ratings. Both boast good

ratings, with over 90% satisfaction measures. Obviously, the aim for call centers is for all contacts to be positive; however, a

90%-95% satisfaction rating is generally the goal.

Companies mostly track customer satisfaction through surveys, both live and with response forms. Leaders use phone surveys, online

surveys, and email surveys to gather satisfaction responses. For the most part, participants track satisfaction internally, without help

from outside vendors.

According to many call center experts, pharma call centers should be doing more by way of customer satisfaction measurement.

Beyond the fact that only 40% of companies even measure customer satisfaction, pharma medical information call centers should

use third-party objective groups to measure performance. These groups offer additional response types as well such as flash surveys,

focus groups and event surveys.

Though there are many ways to combat poor customer satisfaction, one of the more innovative methods is by improving agent

satisfaction. Studies show that more satisfied agents produce better customer satisfaction numbers. With this in mind, medical

information leaders must make sure that agents have competitive compensation packages, have feedback mechanisms to promote

change, and work in enjoyable conditions.

Controlling call quality also aids in creating higher customer satisfaction ratings. Managers should be observing calls regularly,

scoring agents on factors such as customer service skills, knowledge, and ability to navigate internal database systems quickly.

Managers should use these observations to identify agents’ strengths and weaknesses and to develop training plans to improve their

performance.

Companies Included in Report

Abbott
American Academy of CME
Amgen
Bayer
Bristol-Myers Squibb
Boehringer-Ingelheim
Burson-Marsteller
Cephalon
Dey
Gilead Sciences
Johnson & Johnson
Novartis
Pfizer
Procter & Gamble
Sanofi-Aventis

For more information kindly visit
http://www.bharatbook.com/Market-Research-Reports/Evolving-Medical-Information-Call-Centers-through-Performance-Measurement-and-Process-Improvement.html

Next Page »